Information on EC 3.3.2.6 - leukotriene-A4 hydrolase

Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Specify your search results
Mark a special word or phrase in this record:
Select one or more organisms in this record:
Show additional data
Do not include text mining results
Include (text mining) results (more...)
Include results (AMENDA + additional results, but less precise; more...)


The expected taxonomic range for this enzyme is: Opisthokonta

EC NUMBER
COMMENTARY
3.3.2.6
-
RECOMMENDED NAME
GeneOntology No.
leukotriene-A4 hydrolase
REACTION
REACTION DIAGRAM
COMMENTARY
ORGANISM
UNIPROT ACCESSION NO.
LITERATURE
leukotriene A4 + H2O = leukotriene B4
show the reaction diagram
bifunctional enzyme acting as an epoxide hydrolase and also as an aminopeptidase
-
leukotriene A4 + H2O = leukotriene B4
show the reaction diagram
bifunctional enzyme acting as an epoxide hydrolase and also as an aminopeptidase
-
leukotriene A4 + H2O = leukotriene B4
show the reaction diagram
bifunctional enzyme acting as an epoxide hydrolase and also as an aminopeptidase; mechanism
-
leukotriene A4 + H2O = leukotriene B4
show the reaction diagram
bifunctional enzyme acting as an epoxide hydrolase and also as an aminopeptidase
-
leukotriene A4 + H2O = leukotriene B4
show the reaction diagram
bifunctional enzyme acting as an epoxide hydrolase and also as an aminopeptidase; mechanistic models, Glu271 is specifically required for the epoxid hydrolase activity and peptidase activity
-
leukotriene A4 + H2O = leukotriene B4
show the reaction diagram
Asp375 acts as a critical determinant for the stereoselective introduction of the 12R-hydroxyl group, possibly assisted by Gln134 and thus the biological activity of leukotriene B4; bifunctional enzyme acting as an epoxide hydrolase and also as an aminopeptidase
-
leukotriene A4 + H2O = leukotriene B4
show the reaction diagram
bifunctional enzyme acting as an epoxide hydrolase and also as an aminopeptidase
-
leukotriene A4 + H2O = leukotriene B4
show the reaction diagram
bifunctional enzyme acting as an epoxide hydrolase and also as an aminopeptidase; His295, His299, Glu318, Glu271 are amino acids involved in metallic binding and epoxid hydrolase activity, additional Glu296 and Tyr383 are required for the aminopeptidase activity; mechanistic models, Glu271 is specifically required for the epoxid hydrolase activity and peptidase activity
-
leukotriene A4 + H2O = leukotriene B4
show the reaction diagram
bifunctional enzyme acting as an epoxide hydrolase and also as an aminopeptidase; mechanistic models, Glu271 is specifically required for the epoxid hydrolase activity and peptidase activity
-
leukotriene A4 + H2O = leukotriene B4
show the reaction diagram
bifunctional enzyme acting as an epoxide hydrolase and also as an aminopeptidase; enzyme contains two partly overlapping active sites which influence each other; pathway
-
leukotriene A4 + H2O = leukotriene B4
show the reaction diagram
bifunctional enzyme acting as an epoxide hydrolase and also as an aminopeptidase
-
leukotriene A4 + H2O = leukotriene B4
show the reaction diagram
bifunctional enzyme acting as an epoxide hydrolase and also as an aminopeptidase; enzyme contains two partly overlapping active sites which influence each other; Ser415 plays a key role in regulating epoxid hydrolase activity
-
leukotriene A4 + H2O = leukotriene B4
show the reaction diagram
bifunctional enzyme acting as an epoxide hydrolase and also as an aminopeptidase; enzyme contains two partly overlapping active sites which influence each other; the aminopeptidase activity is dependent upon an unmodified cysteine residue, by modifying this cysteine with a small CH3S group it is possible to separate the two enzymatic activities, the aminopeptidase activity and epoxid hydrolase activity, from each other
-
leukotriene A4 + H2O = leukotriene B4
show the reaction diagram
-
-
-
-
REACTION TYPE
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
hydrolysis of ether bond
-
-
-
-
hydrolysis of ether bond
-
-
hydrolysis of ether bond
-
-
hydrolysis of ether bond
-
-
hydrolysis of ether bond
-
-
PATHWAY
KEGG Link
MetaCyc Link
Arachidonic acid metabolism
-
leukotriene biosynthesis
-
Metabolic pathways
-
SYSTEMATIC NAME
IUBMB Comments
(7E,9E,11Z,14Z)-(5S,6S)-5,6-epoxyicosa-7,9,11,14-tetraenoate hydrolase
This is a bifunctional zinc metalloprotease that displays both epoxide hydrolase and aminopeptidase activities [4,6]. It preferentially cleaves tripeptides at an arginyl bond, with dipeptides and tetrapeptides being poorer substrates [6] (see EC 3.4.11.6, aminopeptidase B). It also converts leukotriene A4 into leukotriene B4, unlike EC 3.3.2.10, soluble epoxide hydrolase, which converts leukotriene A4 into 5,6-dihydroxy-7,9,11,14-icosatetraenoic acid [3,4]. In vertebrates, five epoxide-hydrolase enzymes have been identified to date: EC 3.3.2.6 (leukotriene A4 hydrolase), EC 3.3.2.7 (hepoxilin-epoxide hydrolase), EC 3.3.2.9 (microsomal epoxide hydrolase), EC 3.3.2.10 (soluble epoxide hydrolase) and EC 3.3.2.11 (cholesterol-5,6-oxide hydrolase) [5].
SYNONYMS
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
hydrolase, leukotriene A4
-
-
-
-
leukotriene A(4) hydrolase
-
-
-
-
leukotriene A4 hydrolase
-
-
-
-
leukotriene A4 hydrolase
-
-
leukotriene A4 hydrolase
-
-
leukotriene A4 hydrolase
-
contains both hydrolase and aminopeptidase activity
leukotriene A4 hydrolase
-
-
leukotriene A4 hydrolase
Mus musculus BALB/c
-
-
-
leukotriene A4 hydrolase
-
-
leukotriene A4 hydrolase/aminopeptidase
-
-
-
-
leukotriene hydrolase A4
-
-
leukotriene-A4 hydrolase
-
-
leukotriene-A4 hydrolase
-
-
leukotriene-A4 hydrolase
P09960
-
leukotriene-A4 hydrolase
-
-
leukotriene-A4 hydrolase
-
-
LT A4 hydrolase
-
-
LTA-4 hydrolase
-
-
-
-
LTA4 hydrolase
-
-
-
-
LTA4 hydrolase
-
-
LTA4 hydrolase
P30349
-
LTA4H
-
-
-
-
LTA4H
P09960
-
LTA4H
Mus musculus BALB/c
-
-
-
LTA4H
P30349
-
CAS REGISTRY NUMBER
COMMENTARY
90119-07-6
-
ORGANISM
COMMENTARY
LITERATURE
SEQUENCE CODE
SEQUENCE DB
SOURCE
healthy and atopic dogs
-
-
Manually annotated by BRENDA team
the enzyme is encoded in the lta4h locus
-
-
Manually annotated by BRENDA team
recombinant
-
-
Manually annotated by BRENDA team
the enzyme is encoded in the lta4h locus
-
-
Manually annotated by BRENDA team
Balb/c mice
-
-
Manually annotated by BRENDA team
C57BL/6 mice
-
-
Manually annotated by BRENDA team
male ICR mice
-
-
Manually annotated by BRENDA team
NIH Swiss nude mice
-
-
Manually annotated by BRENDA team
Mus musculus BALB/c
Balb/c mice
-
-
Manually annotated by BRENDA team
male Sprague Dawley rats
SwissProt
Manually annotated by BRENDA team
GENERAL INFORMATION
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
malfunction
-
enzyme inhibition blocks lung inflammation, antigen uptake by lung dendritic cells and subsequent trafficking of dendritic cells to draining lymph nodes and the lung are decreased upon enzyme inhibition
malfunction
-
LTA4H polymorphisms are involved in pathogenesis of asthma
malfunction
-
the enzyme is linked to inflammation diseases, especially asthma and also rheumatoid arthritis, significant role for LTB4 production in the pathogenesis of asthma, overview. LTB4 and BLT1 may be involved in the steroid resistance experienced by some patients with asthma
malfunction
-
the enzyme is linked to inflammation diseases, especially asthma and rheumatoid arthritis , mouse model, overview
malfunction
P30349
increase of leukotriene synthesis in spinal microglia produced via p38 MAPK plays a role in the generation of neuropathic pain
malfunction
Mus musculus BALB/c
-
enzyme inhibition blocks lung inflammation, antigen uptake by lung dendritic cells and subsequent trafficking of dendritic cells to draining lymph nodes and the lung are decreased upon enzyme inhibition
-
metabolism
-
LTA4H catalyzes the last step in the synthesis of the pro-inflammatory molecule leukotriene B4
metabolism
-
leukotriene A4 hydrolase is a key enzyme in the leukotriene pathway, which hydrolyzes leukotriene A4 to leukotriene B4, a proinflammatory mediator
metabolism
-
leukotriene A4 hydrolase catalyzes the final step in the synthesis of leukotriene B4, LTB4, a potent chemoattractant and proinflammatory eicosanoid
metabolism
-
no difference in LTA4 hydrolase expression in patients with naturally occurring allergic rhinitis compared to controls, suggesting that LTB4 is less important chronically or that LTA4 hydrolase is not the rate-limiting step in its synthesis
metabolism
-
the enzyme takes part in the pathway for the conversion of arachidonic acid to eicosanoids, overview
metabolism
-
LTA4H is a key enzyme in the leukotriene pathway, which catalyzes the final and rate-determining step in the synthesis of LTB4
metabolism
-
the enzyme is involved in the leukotriene metabolism. In the leukotriene biosynthesis, cells expressing 5-lipoxygenase form LTA4 and transfer it to cells expressing LTA4 hydrolase or LTC4 synthase to produce LTB4 or LTC4
physiological function
-
leukotriene A4 hydrolase is involved in recruitment of both CD4+ and CD8+ T cells to inflammation sites, as well as trafficking of dendritic cells to draining lymph nodes
physiological function
-
leukotrienes are involved in antiinflammation via eicosanoids, lipid mediators derived from arachidonic acid including the proinflammatory leukotrienes as well as the anti-inflammatory lipoxins, complex interplay between proinflammatory leukotrienes and antiinflammatory lipoxins. The enzyme is important in the balance between proinflammatory and anti-inflammatory responses in tuberculosis
physiological function
-
the enzyme is involved in the leukotriene metabolism, leukotrienes are lipid mediators of inflammation formed by enzymatic oxidation of arachidonic acid
physiological function
Mus musculus BALB/c
-
leukotriene A4 hydrolase is involved in recruitment of both CD4+ and CD8+ T cells to inflammation sites, as well as trafficking of dendritic cells to draining lymph nodes
-
metabolism
-
LTA4H in reactive oxygen species detoxification pathways and eicosanoid biosynthetic pathways, overview
additional information
-
HIV-1 transforms the monocyte plasma membrane proteome including also cytosolic LTA4H, the process is linked to cell viability, overview
additional information
-
protection from both tuberculosis and multibacillary leprosy is associated with heterozygosity for LTA4H polymorphisms
SUBSTRATE
PRODUCT                      
REACTION DIAGRAM
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
(Substrate)
LITERATURE
(Substrate)
COMMENTARY
(Product)
LITERATURE
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
(7E,9E,11Z,14Z)-(5S,6S)-5,6-epoxyicosa-7,9,11,14-tetraenoate + H2O
(6Z,8E,10E,14Z)-(5S,12R)-5,12-dihydroxyicosa-6,8,10,14-tetraenoate
show the reaction diagram
-
-
-
-
?
(7E,9E,11Z,14Z)-(5S,6S)-5,6-epoxyicosa-7,9,11,14-tetraenoate + H2O
(6Z,8E,10E,14Z)-(5S,12R)-5,12-dihydroxyicosa-6,8,10,14-tetraenoate
show the reaction diagram
-
-
-
-
?
(7E,9E,11Z,14Z)-(5S,6S)-5,6-epoxyicosa-7,9,11,14-tetraenoate + H2O
(6Z,8E,10E,14Z)-(5S,12R)-5,12-dihydroxyicosa-6,8,10,14-tetraenoate
show the reaction diagram
-
-
-
-
?
(7E,9E,11Z,14Z)-(5S,6S)-5,6-epoxyicosa-7,9,11,14-tetraenoate + H2O
(6Z,8E,10E,14Z)-(5S,12R)-5,12-dihydroxyicosa-6,8,10,14-tetraenoate
show the reaction diagram
-
-
-
-
?
(7E,9E,11Z,14Z)-(5S,6S)-5,6-epoxyicosa-7,9,11,14-tetraenoate + H2O
(6Z,8E,10E,14Z)-(5S,12R)-5,12-dihydroxyicosa-6,8,10,14-tetraenoate
show the reaction diagram
-
substrate for epoxide hydrolase activity
-
-
?
(7E,9E,11Z,14Z)-(5S,6S)-5,6-epoxyicosa-7,9,11,14-tetraenoate + H2O
(6Z,8E,10E,14Z)-(5S,12R)-5,12-dihydroxyicosa-6,8,10,14-tetraenoate
show the reaction diagram
-
substrate for the epoxide hydrolase reaction, in addition LTA4H shows a peptidase activity
-
-
?
Ala-4-nitroanilide + H2O
Ala + 4-nitroaniline
show the reaction diagram
-
-
-
-
?
Arg-Ala-Arg + H2O
?
show the reaction diagram
-
-
-
-
?
Arg-Ser-Arg + H2O
?
show the reaction diagram
-
-
-
-
?
L-Ala-p-nitroanilide + H2O
L-Ala + p-nitroaniline
show the reaction diagram
-
-
-
-
?
L-alanine 2-naphthylamide + H2O
L-alanine + 2-naphthylamine
show the reaction diagram
-
-
-
-
?
L-alanine-4-nitroanilide + H2O
L-alanine + 4-nitroaniline
show the reaction diagram
-
-
-
-
?
L-Arg-p-nitroanilide + H2O
L-Arg + p-nitroaniline
show the reaction diagram
-
-
-
-
?
L-arginine 2-naphthylamide + H2O
L-arginine + 2-naphthylamine
show the reaction diagram
-
-
-
-
?
L-isoleucine 2-naphthylamide + H2O
L-isoleucine + 2-naphthylamine
show the reaction diagram
-
-
-
-
?
L-leucine 2-naphthylamide + H2O
L-leucine + 2-naphthylamine
show the reaction diagram
-
-
-
-
?
L-methionine 2-naphthylamide + H2O
L-methionine + 2-naphthylamine
show the reaction diagram
-
-
-
-
?
L-valine 2-naphthylamide + H2O
L-valine + 2-naphthylamine
show the reaction diagram
-
-
-
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
-
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
-
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
-
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
-
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
-
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
-
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
-
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
-
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
-
-
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
-
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
-
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
-
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
-
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
-
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
-
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
-
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
-
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
-
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
-
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
-
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
-
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
-
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
-
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
-
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
-
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
-
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
-
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
-
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
-
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
-
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
-
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
-
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
-
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
-
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
-
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
-
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
-
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
P09960
-
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
-
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
-
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
-
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
-
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
-
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
-
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
-
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
-
-
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
-
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
-
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
-
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
-
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
-
-
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
-
-
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
-
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
-
-
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
P30349
-
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
P30349
-
-
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
P19602
-
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
-
i.e. LTB4, a potent inflammatory mediator originating from membrane-derived arachidonic acid
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
-
i.e. LTB4, a powerful proinflammatory agent
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
-
LTB4 is an endogenous itch mediator in the skin and is involved in the pruritus response in allergic reactions
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
highly specific
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
i.e. 5(S)-trans-5,6-oxido-7,9-trans-11,14-cis-eicosatetraenoic acid
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
model for the binding of leukotriene A4 to the active site
-
-
-
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
model for the binding of leukotriene A4 to the active site
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
model for the binding of leukotriene A4 to the active site
mutants of Tyr378 are able to generate, not only leukotriene B4, but also (5S,12R)-dihydroxy-6,10-trans-8,14-cis-eicosatetraenoic acid, in a yield of about 20-30%
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
one of the physiologically important processes in the arachidonic acid biosynthetic pathway, leukotriene B4 is a proinflammatory mediator which stimulates adhesion of circulating neutrophils to vascular endothelium and directs their migration towards sites of inflammation
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
central enzyme in leukotriene B4 formation, it is likely to be involved in transcellular leukotriene formation
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
biosynthesis of leukotriene B4
-
-
-
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
biosynthesis of leukotriene B4
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
biosynthesis of leukotriene B4
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
biosynthesis of leukotriene B4
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
biosynthesis of leukotriene B4
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
biosynthesis of leukotriene B4
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
biosynthesis of leukotriene B4
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
biosynthesis of leukotriene B4
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
biosynthesis of leukotriene B4
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
biosynthesis of leukotriene B4
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
biosynthesis of leukotriene B4
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
biosynthesis of leukotriene B4
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
biosynthesis of leukotriene B4
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
biosynthesis of leukotriene B4
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
biosynthesis of leukotriene B4
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
biosynthesis of leukotriene B4
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
biosynthesis of leukotriene B4
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
biosynthesis of leukotriene B4
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
biosynthesis of leukotriene B4
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
P09960
biosynthesis of leukotriene B4
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
biosynthesis of leukotriene B4
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
biosynthesis of leukotriene B4
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
biosynthesis of leukotriene B4
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
biosynthesis of leukotriene B4
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
biosynthesis of leukotriene B4
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
biosynthesis of leukotriene B4
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
biosynthesis of leukotriene B4
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
biosynthesis of leukotriene B4
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
biosynthesis of leukotriene B4
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
biosynthesis of leukotriene B4
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
biosynthesis of leukotriene B4
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
biosynthesis of leukotriene B4
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
biosynthesis of leukotriene B4
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
biosynthesis of leukotriene B4
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
P30349
biosynthesis of leukotriene B4
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
P19602
biosynthesis of leukotriene B4
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
leukotriene A4 hydrolase catalyzes the final step in the synthesis of leukotriene B4, a potent chemoattractant and proinflammatory eicosanoid
-
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
leukotriene A4 hydrolase catalyzes the final step in the synthesis of leukotriene B4, a potent chemoattractant and proinflammatory eicosanoid. LTB4 functions as a macrophage chemoattractant in the zebrafish, injection into the hindbrain ventricle of wild-type arvae induces rapid recruitment of macrophages
-
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
LTA4
LTB4
-
?
leukotriene A4 + H2O
(5S,6S)-dihydroxy-7,9-trans-11,14-cis-eicosatetraenoic acid
show the reaction diagram
-
-
i.e. DHETE
?
leukotriene A4 + H2O
leukotriene B4 + (5S,12R)-dihydroxy-6,10-trans-8,14,cis-eicosatetraenoic acid
show the reaction diagram
-
-
90% leukotriene B4 and 10% (5S,12R)-dihydroxy-6,10-trans-8,14,cis-eicosatetraenoic acid
?
leukotriene A4 + H2O
(5S,6S)-dihydroxy-7,9-trans-11,14-cis-eicosatetraenoic acid + leukotriene B4 + (5S,12R)-dihydroxy-6,10-trans-8,14,cis-eicosatetraenoic acid
show the reaction diagram
-
-
when large amounts of enzyme are incubated with leukotriene A4: 72% (5S,6S)-dihydroxy-7,9-trans-11,14-cis-eicosatetraenoic acid, 18% leukotriene B4 and 10% (5S,12R)-dihydroxy-6,10-trans-8,14,cis-eicosatetraenoic acid
?
leukotriene A5 + H2O
?
show the reaction diagram
-
i.e. 5(S)-trans-5,6-oxido-7,9-trans-11,14,17-cis-eicosatetraenoic acid
-
-
?
proline-4-nitroanilide + H2O
proline + 4-nitroaniline
show the reaction diagram
-
-
-
-
?
lysine-4-nitroanilide + H2O
lysine + 4-nitroaniline
show the reaction diagram
-
-
-
-
?
additional information
?
-
-
-
-
-
-
additional information
?
-
-
-
-
-
-
additional information
?
-
-
-
-
-
-
additional information
?
-
P09960
-
-
-
-
additional information
?
-
-
-
-
-
-
additional information
?
-
-
-
-
-
-
additional information
?
-
-
-
-
-
-
additional information
?
-
-
neutrophil LTA4 hydrolase also converts LTA5 to LTB5, less efficiently than LTA4 to LTB4
-
-
-
additional information
?
-
-
either glutamic or glutamine moiety at amino acid 297 is required for full LTA4 hydrolase activity, free carboxylic acid of glutamic acid is essential for aminopeptidase
-
-
-
additional information
?
-
-
not: glycine-4-nitroanilide, glutamyl-4-nitroanilide, valine-4-nitroanilide
-
-
-
additional information
?
-
-
the aminopeptidase activity accepts a variety of substrates and certain arginyl di- and tri-peptides as well as p-nitroanilide derivates of Ala and Arg
-
-
-
additional information
?
-
-
possible proteolytic function of the enzyme may be limited to the extracellular space
-
-
-
additional information
?
-
-
LTA4H is a zinc metalloprotease
-
-
-
NATURAL SUBSTRATES
NATURAL PRODUCTS
REACTION DIAGRAM
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
(Substrate)
LITERATURE
(Substrate)
COMMENTARY
(Product)
LITERATURE
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
(7E,9E,11Z,14Z)-(5S,6S)-5,6-epoxyicosa-7,9,11,14-tetraenoate + H2O
(6Z,8E,10E,14Z)-(5S,12R)-5,12-dihydroxyicosa-6,8,10,14-tetraenoate
show the reaction diagram
-
-
-
-
?
(7E,9E,11Z,14Z)-(5S,6S)-5,6-epoxyicosa-7,9,11,14-tetraenoate + H2O
(6Z,8E,10E,14Z)-(5S,12R)-5,12-dihydroxyicosa-6,8,10,14-tetraenoate
show the reaction diagram
-
-
-
-
?
(7E,9E,11Z,14Z)-(5S,6S)-5,6-epoxyicosa-7,9,11,14-tetraenoate + H2O
(6Z,8E,10E,14Z)-(5S,12R)-5,12-dihydroxyicosa-6,8,10,14-tetraenoate
show the reaction diagram
-
-
-
-
?
(7E,9E,11Z,14Z)-(5S,6S)-5,6-epoxyicosa-7,9,11,14-tetraenoate + H2O
(6Z,8E,10E,14Z)-(5S,12R)-5,12-dihydroxyicosa-6,8,10,14-tetraenoate
show the reaction diagram
-
-
-
-
?
(7E,9E,11Z,14Z)-(5S,6S)-5,6-epoxyicosa-7,9,11,14-tetraenoate + H2O
(6Z,8E,10E,14Z)-(5S,12R)-5,12-dihydroxyicosa-6,8,10,14-tetraenoate
show the reaction diagram
-
substrate for epoxide hydrolase activity
-
-
?
(7E,9E,11Z,14Z)-(5S,6S)-5,6-epoxyicosa-7,9,11,14-tetraenoate + H2O
(6Z,8E,10E,14Z)-(5S,12R)-5,12-dihydroxyicosa-6,8,10,14-tetraenoate
show the reaction diagram
-
substrate for the epoxide hydrolase reaction, in addition LTA4H shows a peptidase activity
-
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
-
-
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
-
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
-
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
-
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
-
-
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
-
-
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
P30349
-
-
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
-
i.e. LTB4, a potent inflammatory mediator originating from membrane-derived arachidonic acid
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
-
i.e. LTB4, a powerful proinflammatory agent
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
-
LTB4 is an endogenous itch mediator in the skin and is involved in the pruritus response in allergic reactions
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
one of the physiologically important processes in the arachidonic acid biosynthetic pathway, leukotriene B4 is a proinflammatory mediator which stimulates adhesion of circulating neutrophils to vascular endothelium and directs their migration towards sites of inflammation
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
central enzyme in leukotriene B4 formation, it is likely to be involved in transcellular leukotriene formation
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
biosynthesis of leukotriene B4
-
-
-
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
biosynthesis of leukotriene B4
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
biosynthesis of leukotriene B4
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
biosynthesis of leukotriene B4
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
biosynthesis of leukotriene B4
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
biosynthesis of leukotriene B4
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
biosynthesis of leukotriene B4
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
biosynthesis of leukotriene B4
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
biosynthesis of leukotriene B4
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
biosynthesis of leukotriene B4
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
biosynthesis of leukotriene B4
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
biosynthesis of leukotriene B4
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
biosynthesis of leukotriene B4
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
biosynthesis of leukotriene B4
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
biosynthesis of leukotriene B4
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
biosynthesis of leukotriene B4
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
biosynthesis of leukotriene B4
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
biosynthesis of leukotriene B4
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
biosynthesis of leukotriene B4
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
P09960
biosynthesis of leukotriene B4
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
biosynthesis of leukotriene B4
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
biosynthesis of leukotriene B4
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
biosynthesis of leukotriene B4
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
biosynthesis of leukotriene B4
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
biosynthesis of leukotriene B4
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
biosynthesis of leukotriene B4
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
biosynthesis of leukotriene B4
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
biosynthesis of leukotriene B4
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
biosynthesis of leukotriene B4
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
biosynthesis of leukotriene B4
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
biosynthesis of leukotriene B4
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
biosynthesis of leukotriene B4
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
biosynthesis of leukotriene B4
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
biosynthesis of leukotriene B4
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
P30349
biosynthesis of leukotriene B4
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
P19602
biosynthesis of leukotriene B4
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
leukotriene A4 hydrolase catalyzes the final step in the synthesis of leukotriene B4, a potent chemoattractant and proinflammatory eicosanoid
-
-
?
leukotriene A4 + H2O
leukotriene B4
show the reaction diagram
-
leukotriene A4 hydrolase catalyzes the final step in the synthesis of leukotriene B4, a potent chemoattractant and proinflammatory eicosanoid. LTB4 functions as a macrophage chemoattractant in the zebrafish, injection into the hindbrain ventricle of wild-type arvae induces rapid recruitment of macrophages
-
-
?
additional information
?
-
-
possible proteolytic function of the enzyme may be limited to the extracellular space
-
-
-
additional information
?
-
-
LTA4H is a zinc metalloprotease
-
-
-
METALS and IONS
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
Br-
-
stimulates peptidase and epoxide hydrolase activity (i.e. conversion of leukotriene A4 into leukotriene B4), SCN- most effective, followed by Cl- and Br-
Cl-
-
stimulates peptidase activity, not epoxide hydrolase activity (i.e. conversion of leukotriene A4 into leukotriene B4), SCN- most effective, followed by Cl- and Br-
Co2+
-
apoenzyme can be restored by addition of Co2+, peptidase activity exceeds that of enzyme reactivated with zinc
Co2+
-
apoenzyme is inactive and can be reactivated by addition of stoichiometric amounts of zinc and cobalt
Thiocyanate
-
stimulates peptidase and epoxide hydrolase activity (i.e. conversion of leukotriene A4 into leukotriene B4), SCN- most effective, followed by Cl- and Br-
Zinc
-
zinc content: 1 mol of zinc per mol of enzyme; zinc protein
Zinc
-
small intestine: 0.99 mol of zinc/mol of enzyme; zinc protein
Zinc
-
recombinant enzyme: 0.7-1 mol of zinc/mol of enzyme; zinc protein
Zinc
-
apoenzyme is inactive and can be reactivated by addition of stoichiometric amounts of zinc and cobalt; zinc content: 1 mol of zinc per mol of enzyme; zinc protein
Zinc
-
zinc protein
Zinc
-
-
Zinc
-
0.8 mol zinc per mol enzyme
Zinc
-
three putative zinc-binding ligands: His340, His344 and Glu363, zinc atom is catalytic and also involved in the maintenance of the structural integrity of the enzyme; zinc protein
Zinc
-
catalytic zinc site with the signature HEXXH-(X)18-E, three zinc binding ligands: His295, His299 and Glu318; zinc protein
Zinc
-
catalytic zinc site with the signature HEXXH-(X)18-E, three zinc binding ligands: His295, His299 and Glu318; zinc content: 1 mol of zinc per mol of enzyme; zinc protein
Zinc
-
catalytic zinc site with the signature HEXXH-(X)18-E, three zinc binding ligands: His295, His299 and Glu318
Zinc
-
the sequence that codes for the zinc-ion-binding motif is identical in the short-from and long-form enzyme mRNAs; zinc protein
Zinc
-
zinc protein
Zn2+
-
-
Zn2+
-
LTA4-h is a bifunctional zinc-dependent metalloenzyme
Zn2+
-
the enzyme contains zinc
Zn2+
-
contains zinc
Zn2+
-
LTA4H is a zinc metalloprotease
INHIBITORS
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
IMAGE
(1-[2-[4-(benzooxazol-2-yloxy)phenoxy]ethyl]piperidin-4-yl)methanol
-
-
(1-[2-[4-(benzothiazol-2-yloxy)phenoxy]ethyl]piperidin-4-yl)-carbamic acid tert-butyl ester
-
-
(1-[2-[4-(benzothiazol-2-yloxy)phenoxy]ethyl]piperidin-4-yl)-methanol
-
-
(2R)-2-([4-[4-(thiophen-2-yl)benzyl]phenoxy]methyl)piperidine
-
-
-
(2R)-2-([4-[4-(thiophen-3-yl)benzyl]phenoxy]methyl)piperidine
-
-
-
(2R)-2-([4-[4-(thiophen-3-yl)phenoxy]phenoxy]methyl)piperidine
-
-
-
(2R)-2-[(4-phenoxyphenoxy)methyl]piperidine
-
-
(2R)-2-[[(2S)-2-methyl-3-sulfanylpropanoyl]amino]-3-[(4-nitrobenzyl)sulfanyl]propanoic acid
-
-
(2R)-2-[[(2S)-2-methyl-3-sulfanylpropanoyl]amino]-3-[(4-phenoxybenzyl)sulfanyl]propanoic acid
-
-
(2R)-2-[[(2S)-2-methyl-3-sulfanylpropanoyl]amino]-3-[(4-propylbenzyl)sulfanyl]propanoic acid
-
-
(2R)-2-[[(2S)-2-methyl-3-sulfanylpropanoyl]amino]-3-[[4-(trifluoromethoxy)benzyl]sulfanyl]propanoic acid
-
-
(2R)-2-[[(2S)-2-methyl-3-sulfanylpropanoyl]amino]-3-[[4-(trifluoromethyl)benzyl]sulfanyl]propanoic acid
-
-
(2R)-2-[[4-(4-chlorobenzyl)phenoxy]methyl]piperidine
-
-
-
(2R)-2-[[4-(4-chlorophenoxy)phenoxy]methyl]-1-(1,2,4-oxadiazol-2(3H)-ylmethyl)piperidine
-
-
-
(2R)-2-[[4-(4-chlorophenoxy)phenoxy]methyl]piperidine
-
-
-
(2R)-2-[[4-(4-fluorophenoxy)phenoxy]methyl]piperidine
-
-
(2R)-2-[[4-(biphenyl-4-yloxy)phenoxy]methyl]piperidine
-
-
(2R)-3-(benzylsulfanyl)-2-[[(2S)-2-methyl-3-sulfanylpropanoyl]amino]propanoic acid
-
-
(2R)-3-[(4-bromobenzyl)sulfanyl]-2-[[(2S)-2-methyl-3-sulfanylpropanoyl]amino]propanoic acid
-
-
(2R)-3-[(4-chlorobenzyl)sulfanyl]-2-[[(2S)-2-methyl-3-sulfanylpropanoyl]amino]propanoic acid
-
-
(2R)-3-[(4-cyanobenzyl)sulfanyl]-2-[[(2S)-2-methyl-3-sulfanylpropanoyl]amino]propanoic acid
-
-
(2R)-3-[(4-ethoxybenzyl)sulfanyl]-2-[[(2S)-2-methyl-3-sulfanylpropanoyl]amino]propanoic acid
-
-
(2R)-3-[(4-ethylbenzyl)sulfanyl]-2-[[(2S)-2-methyl-3-sulfanylpropanoyl]amino]propanoic acid
-
-
(2R)-3-[(4-fluorobenzyl)sulfanyl]-2-[[(2S)-2-methyl-3-sulfanylpropanoyl]amino]propanoic acid
-
-
(2R)-3-[(4-iodobenzyl)sulfanyl]-2-[[(2S)-2-methyl-3-sulfanylpropanoyl]amino]propanoic acid
-
-
(2R)-3-[(4-methoxybenzyl)sulfanyl]-2-[[(2S)-2-methyl-3-sulfanylpropanoyl]amino]propanoic acid
-
-
(2R)-3-[(4-methylbenzyl)sulfanyl]-2-[[(2S)-2-methyl-3-sulfanylpropanoyl]amino]propanoic acid
-
-
(2R)-3-[(biphenyl-4-ylmethyl)sulfanyl]-2-[[(2S)-2-methyl-3-sulfanylpropanoyl]amino]propanoic acid
-
-
(2R)-3-[[3-(dimethylamino)benzyl]sulfanyl]-2-[[(2S)-2-methyl-3-sulfanylpropanoyl]amino]propanoic acid
-
-
(2R)-3-[[4-(1-methylethyl)benzyl]sulfanyl]-2-[[(2S)-2-methyl-3-sulfanylpropanoyl]amino]propanoic acid
-
-
(2R)-3-[[4-(dimethylamino)benzyl]sulfanyl]-2-[(3-sulfanylbutanoyl)amino]propanoic acid
-
-
(2R)-3-[[4-(dimethylamino)benzyl]sulfanyl]-2-[(3-sulfanylpropanoyl)amino]propanoic acid
-
-
(2R)-3-[[4-(dimethylamino)benzyl]sulfanyl]-2-[(4-sulfanylbutanoyl)amino]propanoic acid
-
-
(2R)-3-[[4-(dimethylamino)benzyl]sulfanyl]-2-[(sulfanylacetyl)amino]propanoic acid
-
-
(2R)-3-[[4-(dimethylamino)benzyl]sulfanyl]-2-[[(2R)-2-methyl-3-sulfanylpropanoyl]amino]propanoic acid
-
-
(2R)-3-[[4-(dimethylamino)benzyl]sulfanyl]-2-[[(2R)-2-sulfanylpropanoyl]amino]propanoic acid
-
-
(2R)-3-[[4-(dimethylamino)benzyl]sulfanyl]-2-[[(2S)-2-methyl-3-sulfanylpropanoyl]amino]propanoic acid
-
SA6541
(2R)-3-[[4-(dimethylamino)benzyl]sulfanyl]-2-[[(2S)-2-sulfanylpropanoyl]amino]propanoic acid
-
-
(2R)-3-[[4-(methoxysulfinyl)benzyl]sulfanyl]-2-[[(2S)-2-methyl-3-sulfanylpropanoyl]amino]propanoic acid
-
-
(2R)-3-[[4-(methylsulfanyl)benzyl]sulfanyl]-2-[[(2S)-2-methyl-3-sulfanylpropanoyl]amino]propanoic acid
-
-
(2S)-1-[(2R)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid
-
5% inhibition at 1 mM
(2S)-1-[(2R)-2-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid
-
-
(2S)-2-([4-[4-(trifluoromethyl)phenoxy]phenoxy]methyl)piperidine
-
-
(2S)-2-amino-5-oxo-5-[(4-phenoxyphenyl)amino]-1-pentanesulfonic acid
-
-
(2S)-2-amino-N-[4-(phenylmethoxy)phenyl]-3-[4-(1H-imidazole)]propanamide dihydrochloride
-
-
(2S)-2-amino-N-[4-(phenylmethoxy)phenyl]-propanamide hydrochloride
-
-
(2S)-2-amino-N-[4-(phenylmethoxy)phenyl]benzenepropanamide hydrochloride
-
-
(2S)-2-[(4-benzylphenoxy)methyl]piperidine
-
-
-
(2S)-2-[(4-phenoxyphenoxy)methyl]piperidine
-
-
(2S)-2-[[4-(4-chlorobenzyl)phenoxy]methyl]piperidine
-
-
-
(2S)-2-[[4-(biphenyl-4-yloxy)phenoxy]methyl]piperidine
-
-
(2S)-3-[[4-(dimethylamino)benzyl]sulfanyl]-2-[[(2S)-2-methyl-3-sulfanylpropanoyl]amino]propanoic acid
-
-
(2S)-4-[[4-(dimethylamino)benzyl]sulfanyl]-2-[[(2S)-2-methyl-3-sulfanylpropanoyl]amino]butanoic acid
-
-
(2S)-N-[4-(phenylmethoxy)phenyl]-2-pyrrolidinecarboxamide hydrochloride
-
-
(2S,3S)-2-amino-3-methyl-N-[4-(phenylmethoxy)-phenyl]pentanamide
-
-
(2S,4R)-3-(2-methyl-3-sulfanylpropanoyl)-2-naphthalen-1-yl-1,3-thiazolidine-4-carboxylic acid
-
58% inhibition at 1 mM
(2S,4S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]-4-[(2-phenylethyl)sulfanyl]pyrrolidine-2-carboxylic acid
-
-
(2S,4S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]-4-[(3-phenylpropyl)sulfanyl]pyrrolidine-2-carboxylic acid
-
-
(2S,4S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]-4-[(naphthalen-1-ylmethyl)sulfanyl]pyrrolidine-2-carboxylic acid
-
-
(2S,4S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]-4-[(naphthalen-2-ylmethyl)sulfanyl]pyrrolidine-2-carboxylic acid
-
-
(2S,4S)-4-(benzylsulfanyl)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid
-
-
(2S,4S)-4-[(2-methylbenzyl)sulfanyl]-1-[(2S)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid
-
-
(2S,4S)-4-[(3-methylbenzyl)sulfanyl]-1-[(2S)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid
-
-
(2S,4S)-4-[[4-(methylsulfanyl)benzyl]sulfanyl]-1-[(2S)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid
-
-
(4-fluorophenyl)(pyridin-4-yl)methanone
-
-
(4R)-2-furan-2-yl-3-[(2S)-2-methyl-3-sulfanylpropanoyl]-1,3-thiazolidine-4-carboxylic acid
-
36% inhibition at 1 mM
(4R)-3-[(2R)-2-methyl-3-sulfanylpropanoyl]-1,3-thiazolidine-4-carboxylic acid
-
18% inhibition at 1 mM
(4R)-3-[(2S)-2-methyl-3-sulfanylpropanoyl]-1,3-thiazolidine-4-carboxylic acid
-
58% inhibition at 1 mM
(4R)-3-[(2S)-2-methyl-3-sulfanylpropanoyl]-2-pyridin-4-yl-1,3-thiazolidine-4-carboxylic acid
-
25% inhibition at 1 mM
(4R)-3-[(2S)-2-methyl-3-sulfanylpropanoyl]-2-thiophen-2-yl-1,3-thiazolidine-4-carboxylic acid
-
14% inhibition at 1 mM
(4R)-4-[[4-(1-methylethyl)benzyl]sulfanyl]-1-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-proline
-
-
(4R)-N-mercaptoacylthiazolidine-4-carboxylic acid
-
-
-
(4S)-4,5-diamino-N-(4-phenoxyphenyl)pentanamide
-
-
(4S)-4-([2-[4-(1-methylethyl)phenyl]ethyl]sulfanyl)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-proline
-
-
(4S)-4-([3-[4-(1-methylethyl)phenyl]propyl]sulfanyl)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-proline
-
-
(4S)-4-amino-4-(2-(1,3,4-triazolyl))-N-(4-phenoxyphenyl)butanamide trifluoroacetate
-
-
(4S)-4-amino-5-(1-phthalimido)-N-(4-phenoxyphenyl)pentanamide trifluoroacetate
-
-
(4S)-4-amino-5-(1H-pyrrol-1-yl)-N-(4-phenoxyphenyl)pentanamide bistrifluoroacetate
-
-
(4S)-4-amino-5-(2-thio-5-amino-1,3,4-thiadiazol-2-yl)-N-(4-phenoxyphenyl)pentanamide bistrifluoroacetate
-
-
(4S)-4-amino-5-hydroxy-N-(4-phenoxyphenyl)pentanamide
-
-
(4S)-4-amino-5-methoxy-N-(4-phenoxyphenyl)-pentanamide
-
-
(4S)-4-[(4-cyclohexylbenzyl)sulfanyl]-1-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-proline
-
-
(4S)-4-[(4-tert-butylbenzyl)sulfanyl]-1-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-proline
-
-
(4S)-4-[[4-(1-methylethyl)benzyl]sulfanyl]-1-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-proline
-
-
(R)-2-(4-benzylphenoxymethyl)pyrrolidine
-
-
(R)-2-[4-(4-chlorophenoxy)phenoxymethyl]pyrrolidine
-
-
(R)-2-[4-(4-thiophene-3-ylbenzoyl)phenoxymethyl]pyrrolidine
-
-
(S)-2-((S)-2-(2-(((R)-1-amino-2-phenylethyl)(hydroxy)phosphoryl)acetamido)-3-phenylpropanamido)-3-phenylpropanoic acid
-
RB3041, tight slow-binding LTA4H inhibitor
(S)-2-((S)-2-(2-(((R)-1-aminoethyl)(hydroxy)phosphoryl)acetamido)-3-(biphenyl-4-yl)propanamido)propanoic acid
-
RB3040, tight slow-binding LTA4H inhibitor
1'-[2-[4-(benzothiazol-2-yloxy)phenoxy]ethyl][1,4']bipiperidinyl-2-one
-
-
1,10-phenanthroline
-
-
1-(1-[2-[4-(benzothiazol-2-yloxy)phenoxy]ethyl]piperidin-4-yl)pyrrolidin-2-one
-
-
1-(1-[2-[4-(benzothiazol-2-yloxy)phenyl]ethyl]piperidin-4-yl)pyrrolidin-2-one
-
-
1-(2,2'-bithiophen-5-yl)methanamine
-
-
1-(2-(4-(2-(trifluoromethyl)phenoxy)phenoxy)ethyl)pyrrolidine
-
dual target inhibitor against cyclooxygenase COX-2 and leukotriene A4 hydrolyase in the enzyme assays and the human whole blood assay with IC50 values in the micromolar to submicromolar range. Inhibitor shows good selectivity for COX-2 over COX-1
-
1-(2-(4-(2-nitrophenoxy)phenoxy)ethyl)pyrrolidine
-
dual target inhibitor against cyclooxygenase COX-2 and leukotriene A4 hydrolyase in the enzyme assays and the human whole blood assay with IC50 values in the micromolar to submicromolar range. Inhibitor shows good selectivity for COX-2 over COX-1
-
1-(2-(4-(4-chlorophenoxy)phenoxy)ethyl)pyrrolidine
-
-
-
1-(2-(4-(4-fluorophenoxy)phenoxy)ethyl)pyrrolidine
-
-
-
1-(2-(4-(4-nitrophenoxy)phenoxy)ethyl)pyrrolidine
-
-
-
1-(2-(4-phenoxyphenoxy)ethyl)pyrrolidine
-
i.e. nimesulide
-
1-(3,4-dihydro-2H-1,5-benzodioxepin-7-yl)-2-[[4-(furan-2-yl)-5-hydroxy-4H-1,2,4-triazol-3-yl]sulfanyl]ethanone
-
compound identified by pharmacophore modeling, binds both human leukotriene hydrolase hLTA4H and the human leukotriene C4 synthase hLTC4S with good binding characteristics
1-benzyl-3-[(4-benzylphenoxy)methyl]piperazine
-
-
-
1-chloro-2,4-dinitrobenzene
-
weak
1-[1-[4-(benzothiazol-2-yloxy)benzyl]piperidin-4-yl]pyrrolidin-2-one
-
-
1-[2-(1H-indol-5-yloxy)ethyl]piperidine-4-carboxylic acid
-
-
1-[2-[4-(benzooxazol-2-yloxy)phenoxy]ethyl]-4-phenylpiperidin-4-ol
-
-
1-[2-[4-(benzooxazol-2-yloxy)phenoxy]ethyl]piperidin-4-ol
-
-
1-[2-[4-(benzothiazol-2-yloxy)phenoxy]ethyl]-4-phenylpiperidin-4-ol
-
-
1-[2-[4-(benzothiazol-2-yloxy)phenoxy]ethyl]piperidin-4-ol
-
-
1-[2-[4-(benzothiazol-2-yloxy)phenoxy]ethyl]piperidin-4-ylamine
-
-
1-[2-[4-(benzothiazol-2-yloxy)phenoxy]ethyl]piperidine-4-carboxylic acid amide
-
-
1-[2-[4-(benzothiazol-2-yloxy)phenyl]ethyl]piperidin-4-ol
-
-
1-[2-[4-(benzothiazol-2-yloxy)phenyl]ethyl]piperidine-4-carboxylic acid amide
-
-
1-[4-(1,3-benzothiazol-2-yloxy)benzyl]piperidine-4-carboxylic acid
-
JNJ-27265732
-
1-[4-(benzothiazol-2-yloxy)benzyl]piperidin-4-ol
-
-
1-[4-(benzothiazol-2-yloxy)benzyl]piperidine-4-carboxylic acid
-
-
1-[4-(benzothiazol-2-yloxy)benzyl]piperidine-4-carboxylic acid amide
-
-
1-[4-(thiophen-2-yl)phenyl]methanamine
-
-
-
14,15-Leukotriene A4
-
-
1H-indol-5-ol
-
-
2,3-Butanedione
-
preincubation with bestatin partially protects enzyme from inactivation
2,4-dimethyl-N-[[2-(thiophen-2-yl)-1,3-thiazol-4-yl]methyl]-1,3-thiazole-5-sulfonamide
-
compound identified by pharmacophore modeling, binds both human leukotriene hydrolase hLTA4H and the human leukotriene C4 synthase hLTC4S with good binding characteristics
2-(4-piperidin-1-ylmethylphenoxy)benzothiazole
-
-
2-amino-N-[4-(phenylmethoxy)phenyl]-acetamide
-
-
2-bromo-4-[(methyl[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]amino)methyl]benzoic acid
-
-
2-fluoro-4-[(methyl[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]amino)methyl]benzoic acid
-
-
2-oxo-3-amino carboxylic esters
-
contain a transition state mimic of the enzyme-catalyzed amide cleavage as a core and additional complementary components which resemble the hydrophobic nature of the conjugated polyene system of the natural substrate LTA4
-
2-oxo-3-amino carboxylic esters
-
comparison of inhibition of mutant and wild-type enzymes
-
2-oxo-3-amino carboxylic esters
-
-
-
2-oxo-3-amino carboxylic esters
-
-
-
2-oxo-3-amino carboxylic esters
-
-
-
2-[(4-benzylphenoxy)methyl]piperazine
-
-
2-[(4-benzylphenoxy)methyl]piperidine
-
-
2-[(4-phenoxyphenoxy)methyl]piperidine
-
-
-
2-[4-(2-azepan-1-ylethoxy)phenoxy]-1H-benzoimidazole
-
-
2-[4-(2-azepan-1-ylethoxy)phenoxy]benzooxazole
-
-
2-[4-(2-azepan-1-ylethoxy)phenoxy]benzothiazole
-
-
2-[4-(2-morpholin-4-ylethoxy)phenoxy]-1-(2-trimethylsilanylethoxymethyl)-1H-benzoimidazole
-
-
2-[4-(2-morpholin-4-ylethoxy)phenoxy]-1H-benzoimidazole
-
-
2-[4-(2-morpholin-4-ylethoxy)phenoxy]benzooxazole
-
-
2-[4-(2-morpholin-4-ylethoxy)phenoxy]benzothiazole
-
-
2-[4-(2-piperidin-1-ylethoxy)phenoxy]-1H-benzoimidazole
-
-
2-[4-(2-piperidin-1-ylethoxy)phenoxy]benzooxazole
-
-
2-[4-(2-piperidin-1-ylethoxy)phenoxy]benzothiazole
-
-
2-[4-(2-piperidin-1-ylethyl)phenoxy]benzothiazole
-
-
2-[4-(2-pyrrolidin-1-ylethoxy)phenoxy]-1H-benzoimidazole
-
-
2-[4-(2-pyrrolidin-1-ylethoxy)phenoxy]benzooxazole
-
-
2-[4-(2-pyrrolidin-1-ylethoxy)phenoxy]benzothiazole
-
-
2-[4-[4-[2-[1-pyrrolidinyl]ethoxy]phenoxy]phenyl]-oxazole
-
-
2-[[4-methyl-5-([[2-oxo-2-(phenylamino)ethyl]sulfanyl]methyl)-4H-1,2,4-triazol-3-yl]sulfanyl]-N-phenylacetamide
-
compound identified by pharmacophore modeling, binds both human leukotriene hydrolase hLTA4H and the human leukotriene C4 synthase hLTC4S with good binding characteristics
2S-2,6-diamino-N-[4-(phenylmethoxy)phenyl]hexanamide dihydrochloride
-
-
3-(1-[2-[4-(benzothiazol-2-yloxy)phenoxy]ethyl]piperidin-4-yl)oxazolidin-2-one
-
-
3-(1-[2-[4-(benzothiazol-2-yloxy)phenyl]ethyl]piperidin-4-yl)oxazolidin-2-one
-
-
3-(4-benzyloxyphenyl)-2-(R)-amino-1-propanethiol
-
it are about 50 derivates and related structures synthesized and assayed their inhibition of enzyme catalyzes hxdrolysis of L-alanine-4-nitroanilide
-
3-(4-fluorophenyl)-5-[2-methyl-5-(pyrrolidin-1-ylsulfonyl)furan-3-yl]-1,2,4-oxadiazole
-
compound identified by pharmacophore modeling, binds both human leukotriene hydrolase hLTA4H and the human leukotriene C4 synthase hLTC4S with good binding characteristics
3-(benzyloxy)pyridin-2-amine
-
-
3-amino-3,4-dihydro-1H-naphthalen-2-one O-(2-phenylethyl)oxime
-
-
3-amino-3,4-dihydro-1H-naphthalen-2-one O-(3-phenylpropyl)oxime
-
-
3-amino-3,4-dihydro-1H-naphthalen-2-one O-(4-phenylbutyl)oxime
-
-
3-amino-3,4-dihydro-1H-naphthalen-2-one O-(5-phenylpentyl)oxime
-
-
3-fluoro-4-[(methyl[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]amino)methyl]benzoic acid
-
-
3-[(2R)-2-[[4-(4-chlorophenoxy)phenoxy]methyl]piperidin-1-yl]propanoic acid
-
-
-
3-[1-[4-(benzothiazol-2-yloxy)benzyl]piperidin-4-yl]oxazolidin-2-one
-
-
3-[[4-(1-methylethyl)benzyl]sulfanyl]-N-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-valine
-
-
4-((R)-2-(4-(4-chlorophenoxy)phenoxymethyl)pyrrolidin-1-yl)-l-butyric acid
-
-
4-((S)-2-[4-(4-chlorophenoxy)phenoxymethyl]pyrrolidin-1-yl)-butyric acid
-
-
4-(2-amino-1,3-thiazol-4-yl)phenol
-
-
4-([(1R,5S)-3-[(4-benzylphenyl)amino]-8-azabicyclo[3.2.1]oct-8-yl]methyl)benzoic acid
-
-
4-([(1R,5S)-3-[(4-phenoxyphenyl)amino]-8-azabicyclo[3.2.1]oct-8-yl]methyl)benzoic acid
-
-
4-([(2R)-2-[(methyl[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]amino)methyl]pyrrolidin-1-yl]methyl)benzoic acid
-
-
-
4-([2-[(methyl[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]amino)methyl]pyrrolidin-1-yl]methyl)benzoic acid
-
-
4-([4-[([4-[4-(1,3-oxazol-2-yl)phenoxy]phenyl]amino)methyl]piperidin-1-yl]methyl)benzoic acid
-
-
4-([methyl[2-(methyl[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]amino)ethyl]amino]methyl)benzoic acid
-
-
4-([methyl[2-([4-[4-(1,3-oxazol-2-yl)phenoxy]phenyl]amino)ethyl]amino]methyl)benzoic acid
-
-
4-([methyl[3-([2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]amino)propyl]amino]methyl)benzoic acid
-
-
4-([methyl[3-([4-[4-(1,3-oxazol-2-yl)phenoxy]phenyl]amino)propyl]amino]methyl)benzoic acid
-
-
4-([methyl[4-([4-[4-(1,3-oxazol-2-yl)phenoxy]phenyl]amino)cyclohexyl]amino]methyl)benzoic acid
-
-
4-([[2,2-dimethyl-3-(methyl[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]amino)propyl](methyl)amino]methyl)benzoic acid
-
-
4-([[3-(methyl[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]amino)propyl]amino]methyl)benzoic acid
-
-
4-([[3-([2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]amino)propyl]amino]methyl)benzoic acid
-
-
4-([[4-([4-[4-(1,3-oxazol-2-yl)phenoxy]phenyl]amino)cyclohexyl]amino]methyl)benzoic acid
-
-
4-amino-N-[4-(phenylmethoxy)phenyl]butanamide hydrochloride
-
-
4-dimethylamino-N-[4-(phenylmethoxy)phenyl]-butanamide trifluoroacetate
-
-
4-methylamino-N-[4-(phenylmethoxy)phenyl]butanamide trifluoroacetate
-
-
4-[(2R)-2-[[4-(4-chlorophenoxy)phenoxy]methyl]piperidin-1-yl]butanoic acid
-
-
4-[(2R)-2-[[4-(4-chlorophenoxy)phenoxy]methyl]pyrrolidin-1-yl]butanoic acid
-
i.e. DG-051, a phase II clinical candidate
4-[(2R)-2-[[4-(4-chlorophenoxy)phenoxy]methyl]pyrrolidin-1-yl]butanoic acid
-
-
4-[(2R)-2-[[4-(4-chlorophenoxy)phenoxy]methyl]pyrrolidin-1-yl]butanoic acid
-
i.e. DG-051
4-[(2S)-2-([4-(4-chlorophenoxy)phenoxy]methyl)-1-pyrrolidinyl]butanoic acid
-
i.e. DG-051
4-[(2S)-2-([4-[4-(thiophen-3-yl)benzyl]phenoxy]methyl)piperidin-1-yl]butanoic acid
-
-
4-[(2S)-2-[[4-(4-chloro-2-hydroxyphenoxy)phenoxy]methyl]pyrrolidin-1-yl]butanoic acid
-
i.e. DG-051 M1-A, a derivative derived from DG-051
4-[(2S)-2-[[4-(4-chloro-3-hydroxyphenoxy)phenoxy]methyl]pyrrolidin-1-yl]butanoic acid
-
i.e. DG-051 M1-B, a derivative derived from DG-051
4-[(2S)-2-[[4-(4-chlorophenoxy)phenoxy]methyl]-1-oxidopyrrolidin-1-yl]butanoic acid
-
i.e. DG-051 M2, an N-oxide derivative derived from DG-051
4-[(2S)-2-[[4-(4-chlorophenoxy)phenoxy]methyl]piperidin-1-yl]butanoic acid
-
-
-
4-[(4-[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]-1,4-diazepan-1-yl)methyl]benzoic acid
-
-
4-[(4-[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]piperazin-1-yl)methyl]benzoic acid
-
-
4-[(5-[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]-2,5-diazabicyclo[2.2.1]hept-2-yl)methyl]benzoic acid
-
-
4-[(methyl[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]amino)methyl]-3-nitrobenzoic acid
-
-
4-[(methyl[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]amino)methyl]benzoic acid
-
-
4-[(methyl[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]amino)methyl]cyclohexanecarboxylic acid
-
-
4-[(methyl[[(2R)-1-[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]piperidin-2-yl]methyl]amino)methyl]benzoic acid
-
-
4-[(methyl[[(2R)-1-[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]pyrrolidin-2-yl]methyl]amino)methyl]benzoic acid
-
-
4-[(methyl[[(2S)-1-[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]piperidin-2-yl]methyl]amino)methyl]benzoic acid
-
-
4-[(methyl[[(2S)-1-[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]pyrrolidin-2-yl]methyl]amino)methyl]benzoic acid
-
-
4-[2-(methyl[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]amino)ethyl]benzoic acid
-
-
4-[2-[(1R,5S)-3-([4-[4-(1,3-oxazol-2-yl)phenoxy]phenyl]amino)-8-azabicyclo[3.2.1]oct-8-yl]ethyl]benzoic acid
-
-
4-[2-[3-([4-[4-(1,3-oxazol-2-yl)phenoxy]phenyl]amino)piperidin-1-yl]ethyl]benzoic acid
-
-
4-[2-[4-([4-[4-(1,3-oxazol-2-yl)phenoxy]phenyl]amino)piperidin-1-yl]ethyl]benzoic acid
-
-
4-[[(1R,5S)-3-([4-[3-(1,3-oxazol-2-yl)phenoxy]phenyl]amino)-8-azabicyclo[3.2.1]oct-8-yl]methyl]benzoic acid
-
JNJ-26993135
4-[[(1R,5S)-3-([4-[4-(1,3-oxazol-2-yl)phenoxy]phenyl]amino)-8-azabicyclo[3.2.1]oct-8-yl]methyl]benzoic acid
-
-
4-[[(1R,5S)-3-([4-[4-(1,3-thiazol-2-yl)phenoxy]phenyl]amino)-8-azabicyclo[3.2.1]oct-8-yl]methyl]benzoic acid
-
-
4-[[(1R,5S)-3-([4-[4-(1H-pyrrol-1-yl)phenoxy]phenyl]amino)-8-azabicyclo[3.2.1]oct-8-yl]methyl]benzoic acid
-
-
4-[[(1R,5S)-3-([4-[4-(trifluoromethyl)phenoxy]phenyl]amino)-8-azabicyclo[3.2.1]oct-8-yl]methyl]benzoic acid
-
-
4-[[(1R,5S)-3-[[4-(1,3-benzothiazol-2-yloxy)phenyl]amino]-8-azabicyclo[3.2.1]oct-8-yl]methyl]benzoic acid
-
-
4-[[(1R,5S)-3-[[4-(2-chlorophenoxy)phenyl]amino]-8-azabicyclo[3.2.1]oct-8-yl]methyl]benzoic acid
-
-
4-[[(1R,5S)-3-[[4-(2-fluorophenoxy)phenyl]amino]-8-azabicyclo[3.2.1]oct-8-yl]methyl]benzoic acid
-
-
4-[[(1R,5S)-3-[[4-(4-chlorophenoxy)phenyl]amino]-8-azabicyclo[3.2.1]oct-8-yl]methyl]benzoic acid
-
-
4-[[(1R,5S)-3-[[4-(4-fluorophenoxy)phenyl]amino]-8-azabicyclo[3.2.1]oct-8-yl]methyl]benzoic acid
-
-
4-[[(1R,5S)-3-[[4-(4-methoxyphenoxy)phenyl]amino]-8-azabicyclo[3.2.1]oct-8-yl]methyl]benzoic acid
-
-
4-[[(1R,5S)-3-[[4-(benzyloxy)phenyl]amino]-8-azabicyclo[3.2.1]oct-8-yl]methyl]benzoic acid
-
-
4-[[(1R,5S)-3-[[4-(biphenyl-4-yloxy)phenyl]amino]-8-azabicyclo[3.2.1]oct-8-yl]methyl]benzoic acid
-
-
4-[[(1R,5S)-3-[[4-(pyridin-4-ylmethyl)phenyl]amino]-8-azabicyclo[3.2.1]oct-8-yl]methyl]benzoic acid
-
-
4-[[(3-[[2-([4-[(2R)-2-hydroxy-2-phenylethoxy]phenyl]amino)-2-oxoethyl](methyl)amino]propyl)(methyl)amino]methyl]benzoic acid
-
-
4-[[(3R)-3-(methyl[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]amino)pyrrolidin-1-yl]methyl]benzoic acid
-
-
4-[[(3S)-3-(methyl[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]amino)pyrrolidin-1-yl]methyl]benzoic acid
-
-
4-[[3-([4-[4-(1,3-oxazol-2-yl)phenoxy]phenyl]amino)piperidin-1-yl]methyl]benzoic acid
-
-
4-[[3-([4-[4-(1,3-oxazol-2-yl)phenoxy]phenyl]amino)pyrrolidin-1-yl]methyl]benzoic acid
-
-
4-[[4-(1-[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]hydrazino)piperidin-1-yl]methyl]benzoic acid
-
-
4-[[4-(methyl[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]amino)azepan-1-yl]methyl]benzoic acid
-
-
4-[[4-([4-[4-(1,3-oxazol-2-yl)phenoxy]phenyl]amino)azepan-1-yl]methyl]benzoic acid
-
-
4-[[4-([4-[4-(1,3-oxazol-2-yl)phenoxy]phenyl]amino)piperidin-1-yl]methyl]benzoic acid
-
-
4-[[methyl(1-[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]azepan-4-yl)amino]methyl]benzoic acid
-
-
4-[[methyl(1-[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]piperidin-4-yl)amino]methyl]benzoic acid
-
-
4-[[methyl(3-[methyl[2-([4-[4-(1,3-oxazol-2-yl)phenoxy]phenyl]amino)-2-oxoethyl]amino]propyl)amino]methyl]benzoic acid
-
-
4-[[[3-[(2-[[4-(2-fluorophenoxy)phenyl]amino]-2-oxoethyl)(methyl)amino]propyl](methyl)amino]methyl]benzoic acid
-
-
4-[[[3-[(2-[[4-(4-chlorophenoxy)phenyl]amino]-2-oxoethyl)(methyl)amino]propyl](methyl)amino]methyl]benzoic acid
-
-
4-[[[3-[(2-[[4-(4-fluorophenoxy)phenyl]amino]-2-oxoethyl)(methyl)amino]propyl](methyl)amino]methyl]benzoic acid
-
-
4-[[[3-[[2-[(4-benzylphenyl)amino]-2-oxoethyl](methyl)amino]propyl](methyl)amino]methyl]benzoic acid
-
-
5-(2-pyrrolidin-1-ylethoxy)-1H-indole
-
-
5-chloro-1H-indole
-
-
5-fluoro-1H-indole
-
-
-
5-oxo-5-[[4-(phenylmethoxy)phenyl]amino]pentanoic acid
-
-
5-[(methyl[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]amino)methyl]furan-2-carboxylic acid
-
-
7,11-trans-9-cis-Leukotriene A4
-
-
7-trans-9,11-cis-Leukotriene A4
-
-
8-Hydroxy-quinoline-5-sulfonic acid
-
-
acetic acid (1-[2-[4-(benzothiazol-2-yloxy)phenyl]ethyl]piperidin-4-ylcarbamoyl)methyl ester
-
-
acetic acid [1-[4-(benzothiazol-2-yloxy)benzyl]piperidin-4-ylcarbamoyl]methyl ester
-
-
Acetic anhydride
-
complete loss of peptidase activity and epoxide hydrolase activity
aminohydroxamic acid
-
-
ammonium sulfate
-
-
benzyl[4-((R)-1-pyrrolidin-2-ylmethoxy)phenyl]amine
-
-
bestatin
-
immediate and reversible effect on isolated enzyme
bestatin
-
no influence
bestatin
-
aminopeptidase activity, leukotriene A4 competes partially
bestatin
-
comparison of inhibition of mutant and wild-type enzymes, mechanism
bestatin
P30349
bestatin inhibits leukotriene B4 biosynthesis in the esophageal tissues
Captopril
-
59% inhibition at 1 mM
citraconic anhydride
-
complete loss of peptidase activity and epoxide hydrolase activity
Co2+
-
reversible by addition of EDTA
DG-051
-
a LTA4H inhibitor, used for therapeutic modulation of the leukotriene synthesis pathway in case of myocardial infarction
diamide/glutathione combination
-
complete loss of peptidase activity and epoxide hydrolase activity
-
dihydroresveratrol
-
-
hydroxamic acid
-
aminopeptidase activity
hydroxamic acid
-
comparison of inhibition of mutant and wild-type enzymes
hydroxamic acid
-
-
iodoacetamide
-
weak
iodoacetic acid
-
weak
JNJ 26993135
-
a selective LTA4H inhibitor, leads to reduction of TH2 cytokines and mucin levels, and blocks mast cell production of LTB4 and suppresses airway hyperresponsiveness
Leu-thiol
-
-
leukotriene A4
-
suicide inactivation
leukotriene A4
-
suicide inactivation via an apparently mechanism-based irreversible binding of leukotriene A4 to the protein in a 1:1 stoichiometry, comparison of inactivation of wild-type and mutant enzymes, Tyr378 is a residue, which is involved in the binding of leukotriene A4
leukotriene A4
-
comparison of inactivation of wild-type and mutant enzymes; suicide inactivation
leukotriene A4
-
leukotriene A4 binds covalently to Tyr378 and blocks epoxide hydrolase and aminopeptidase activities
leukotriene A4
-
inhibits epoxid hydrolase activity and stimulates peptidase activity
leukotriene A4
-
-
leukotriene A4
-
-
leukotriene A4
-
pre-treatment of enzyme by methyl-methane thiosulfonate does not protect against suicide inactivation by leukotriene A4
leukotriene A4 ethyl ester
-
comparison of inactivation of wild-type and mutant enzymes
leukotriene A4 methyl ester
-
comparison of inactivation of wild-type and mutant enzymes
leukotriene A4 methyl ester
-
-
leukotriene A4 methyl ester
-
no influence
methyl methanethiosulfonate
-
inhibition of epoxide hydrolase activity, stimulation of peptidase activity
methyl-methane thiosulfonate
-
inhibits aminopeptidase activity and NaCl stimulates this inactivation, beta-mercaptoethanol reactivates this inactivation, bestatin protects inactivation, little effect on epoxid hydrolase activity
N-(1-[2-[4-(benzothiazol-2-yloxy)phenyl]ethyl]piperidin-4-yl)acetamide
-
-
N-(2-[[6-(4-fluorophenyl)pyridazin-3-yl]amino]ethyl)-1,2-dimethyl-1H-imidazole-4-sulfonamide
-
compound identified by pharmacophore modeling, binds both human leukotriene hydrolase hLTA4H and the human leukotriene C4 synthase hLTC4S with good binding characteristics
N-Acetylimidazole
-
75 min, loss of 92% peptidase activity and 78% of epoxide hydrolase activity, both activities are restored by hydroxylamine and bestatin protects
N-ethylmaleimide
-
-
N-ethylmaleimide
-
weak
N-mercaptoacyl-L-proline
-
-
-
N-methyl-1-[2-(thiophen-2-yl)phenyl]methanamine
-
-
N-[1-[4-(1,3-benzothiazol-2-yloxy)benzyl]piperidin-4-yl]-2-hydroxyacetamide
-
SC-57461A
N-[1-[4-(benzothiazol-2-yloxy)benzyl]piperidin-4-yl]-2-hydroxyacetamide
-
-
N-[1-[4-(benzothiazol-2-yloxy)benzyl]piperidin-4-yl]acetamide
-
-
N-[2-[(furan-2-ylmethyl)sulfanyl]ethyl]-2-[[1-(4-hydroxyphenyl)-1H-tetrazol-5-yl]sulfanyl]acetamide
-
compound identified by pharmacophore modeling, binds both human leukotriene hydrolase hLTA4H and the human leukotriene C4 synthase hLTC4S with good binding characteristics
N-[3(R)-[(hydroxyamino)carbonyl]-2-benzyl-1-oxopropyl]-L-alanine
-
i.e. kelatorphan, potent inhibitor of Zn-metalloenzymes
-
N-[3-(4-benzylphenoxy)propyl]-N-methyl-beta-alanine
-
SA-6541
N-[3-[3-(acetylamino)phenoxy]propyl]-3-[3-(pyridin-2-yl)-1,2,4-oxadiazol-5-yl]propanamide
-
compound identified by pharmacophore modeling, binds both human leukotriene hydrolase hLTA4H and the human leukotriene C4 synthase hLTC4S with good binding characteristics
N-[4-(3-chlorophenyl)-2,5-dioxopiperazin-1-yl]-2-[[4-methyl-5-(pyridin-4-yl)-4H-1,2,4-triazol-3-yl]sulfanyl]acetamide
-
compound identified by pharmacophore modeling, binds both human leukotriene hydrolase hLTA4H and the human leukotriene C4 synthase hLTC4S with good binding characteristics
N1-(2-aminoethyl)-N5-(4-phenoxyphenyl)-L-glutamamide hydrochloride
-
-
N1-(2-carboxyethyl)-N5-(4-phenoxyphenyl)-L-glutamamide trifluoroacetate
-
-
N1-(2-hydroxyethyl)-N5-(4-phenoxyphenyl)-L-glutamamide trifluoroacetate
-
-
N1-(3-carboxypropyl)-N5-(4-phenoxyphenyl)-L-glutamamide trifluoroacetate
-
-
N1-(4-carboxybutyl)-N5-(4-phenoxyphenyl)-L-glutamamide bistrifluoroacetate
-
-
N1-hydroxy-N5-[4-(phenylmethoxy)phenyl]-L-glutamamide trifluoroacetate
-
-
N1-[4-(phenylmethoxy)phenyl]-D-aspartamine
-
-
N1-[4-(phenylmethoxy)phenyl]-D-glutamine trifluoroacetate
-
-
N1-[4-(phenylmethoxy)phenyl]-L-aspartamine trifluoroacetate
-
-
N1-[4-(phenylmethoxy)phenyl]-L-glutamamide hydrochloride
-
-
N1-[4-(phenylmethoxy)phenyl]-L-glutamine trifluoroacetate
-
-
N2-methyl-N-(4-phenoxyphenyl)-N2-[4-(1H-tetrazol-5-yl)benzyl]glycinamide
-
-
N2-methyl-N2-[3-[methyl(4-oxobutyl)amino]propyl]-N-(4-phenoxyphenyl)glycinamide
-
-
N2-methyl-N2-[4-[methyl(4-oxobutyl)amino]butyl]-N-(4-phenoxyphenyl)glycinamide
-
-
N2-[3-(dimethylamino)propyl]-N2-methyl-N-(4-phenoxyphenyl)glycinamide
-
-
N2-[3-[benzyl(methyl)amino]propyl]-N2-methyl-N-(4-phenoxyphenyl)glycinamide
-
-
N2-[4-[(aminooxy)sulfinyl]benzyl]-N2-methyl-N-(4-phenoxyphenyl)glycinamide
-
-
N4-[4-(phenylmethoxy)phenyl]-L-aspartamine trifluoroacetate
-
-
N5-(4-phenoxyphenyl)-L-glutamine
-
-
N5-phenyl-L-glutamamide dihydrochloride
-
-
N5-[(4-phenoxy)-3-pyridyl]-L-glutamamide tristrifluoroacetate
-
-
N5-[3-(phenylmethoxy)phenyl]-L-glutamine methyl ester
-
-
N5-[4-(1H-pyrrol-1-yl)phenyl]-L-glutamamide hydrochloride
-
-
N5-[4-(2-hydroxy-3-phenylpropoxy)phenyl]-L-glutamine trifluoroacetate
-
-
N5-[4-(2-methylphenoxy)phenyl]-L-glutamamide hydrochloride
-
-
N5-[4-(2-oxo-3-phenylpropoxy)phenyl]-L-glutamine trifluoroacetate
-
-
N5-[4-(2-phenylethoxy)phenyl]-L-glutamine
-
-
N5-[4-(3-methylphenoxy)phenyl]-L-glutamamide hydrochloride
-
-
N5-[4-(3-phenylpropoxy)phenyl]-L-glutamine
-
-
N5-[4-(4-(3-furyl)phenoxy)phenyl]-L-glutamamide trifluoroacetate
-
-
N5-[4-(4-methylphenoxy)phenyl]-L-glutamamide hydrochloride
-
-
N5-[4-(cyclohexyloxy)phenyl]-L-glutamamide
-
-
N5-[4-(N-methyl-N-phenylamino)phenyl]-L-glutamine methyl ester trifluoroacetate
-
-
N5-[4-(N-phenylamino)phenyl]-L-glutamine bistrifluoroacetate
-
-
N5-[4-(phenylmethoxy)phenyl]-D-glutamine hydrochloride
-
-
N5-[4-(phenylmethoxy)phenyl]-L-glutamamide trifluoroacetate
-
-
N5-[4-(phenylmethoxy)phenyl]-L-glutamine 1,1-dimethylethyl ester
-
-
N5-[4-(phenylmethoxy)phenyl]-L-glutamine hemitrifluoroacetate
-
-
N5-[4-(phenylmethoxy)phenyl]-L-glutamine methyl ester hydrochloride
-
-
N5-[4-benzylphenyl]-L-glutamamide trifluoroacetate
-
-
N5-[4-methoxyphenyl]-L-glutamine methyl ester trifluoroacetate
-
-
N5-[4-[4-(1H-pyrrol-1-yl)phenoxy]phenyl]-L-glutamine hemitrifluoroacetate
-
-
N6-[4-(4-methylphenoxy)phenyl]-L-homoglutamine trifluoroacetate
-
-
o-phenanthroline
-
-
omega-[(omega-arylalkyl)aryl]alkanoid acids
-
-
-
p-hydroxymercuribenzoate
-
bestatin protects inactivation
Phenylglyoxal
-
preincubation with captopril protects enzyme from inactivation
pyridin-4-yl[4-(2-pyrrolidin-1-ylethoxy)phenyl]methanol
-
-
resveratrol
-
-
S-(4-cyclohexylbenzyl)-N-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-cysteine
-
-
S-(4-tert-butylbenzyl)-N-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-cysteine
-
-
S-[(4-cyclohexylphenyl)(phenyl)methyl]-N-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-cysteine
-
-
S-[1-(4-cyclohexylphenyl)-1-methylethyl]-N-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-cysteine
-
-
S-[1-methyl-1-[4-(1-methylethyl)phenyl]ethyl]-N-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-cysteine
-
-
S-[1-[4-(1-methylethyl)phenyl]butyl]-N-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-cysteine
-
-
S-[1-[4-(1-methylethyl)phenyl]ethyl]-N-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-cysteine
-
-
S-[1-[4-(1-methylethyl)phenyl]pentyl]-N-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-cysteine
-
-
S-[1-[4-(1-methylethyl)phenyl]propyl]-N-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-cysteine
-
-
S-[2-methyl-1-[4-(1-methylethyl)phenyl]propyl]-N-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-cysteine
-
-
S-[4-(diethylamino)benzyl]-N-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-cysteine
-
-
S-[4-(dimethylamino)benzyl]-N-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-cysteine
-
i.e. SA6541, a specific inhibiter of LTA4 hydrolase, that attenuates 5-lipoxygenase metabolite-induced scratching behavior, but does not affect the increase in vascular permeability caused by 5-hydroperoxyeicosatetraenoic acid, 5-HPETE, overview
S-[[4-(1-methylethyl)phenyl](phenyl)methyl]-N-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-cysteine
-
-
SC-57461A
-
-
SC-57461A
-
-
Tetranitromethane
-
preincubation with bestatin prevents the inactivation
thioamine
-
aminopeptidase activity, leukotriene A4 restores
-
thioamine
-
comparison of inhibition of mutant and wild-type enzymes
-
thioamine
-
-
-
Trinitrobenzenesulfonate
-
complete loss of peptidase activity and epoxide hydrolase activity
Zn2+
-
reversible by addition of EDTA
[(2R)-2-[[4-(4-chlorophenoxy)phenoxy]methyl]piperidin-1-yl]acetic acid
-
-
-
[6]-gingerol
-
from ginger, [6]-gingerol suppresses anchorage-independent cancer cell growth by inhibiting LTA4H activity in HCT116 colorectal cancer cells, overview. [6]-Gingerol specifically binds with LTA4H in vitro and ex vivo
[6]-gingerol
-
from ginger, [6]-gingerol suppresses anchorage-independent cancer cell growth by inhibiting LTA4H activity in mice, overview. [6]-Gingerol specifically binds with LTA4H in vitro and ex vivo
methyl-N-[3-[4-(phenylmethyl)-phenoxy]propyl]-beta-alanine
-
-
additional information
-
not: EDTA, dipicolinic acid
-
additional information
-
not diethyl dicarbonate
-
additional information
-
some enzyme inhibitors also affect the cytotoxicity of the anthrax lethal factor on macrophage cell lines
-
additional information
-
not: PMSF, GEMSA, iodoacetamide
-
additional information
-
leukotriene A4 inhibitors based on piperidine and piperazine scaffolds, overview
-
additional information
-
structure-based drug discovery, inhibitor binding and molecular docking, overview
-
additional information
-
inhibitor structure-function analysis, overview
-
additional information
-
combined molecular docking and pharmacophore filtering assay for identification of chemical compounds that can simultaneously inhibit the human leukotriene hydrolase hLTA4H and the human leukotriene C4 synthase hLTC4S enzymes
-
ACTIVATING COMPOUND
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
IMAGE
Albumin
-
stimulates aminopeptidase activity
-
Albumin
-
-
-
Br-
-
stimulates aminopeptidase activity
Cl-
-
stimulates aminopeptidase activity
leukotriene A4
-
stimulates strong aminopeptidase activity via lipid binding site
SCN-
-
stimulates aminopeptidase activity
KM VALUE [mM]
KM VALUE [mM] Maximum
SUBSTRATE
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
IMAGE
0.47
-
alanine-4-nitroanilide
-
pH 7.5, 25C
0.5
-
alanine-4-nitroanilide
-
pH 7.6, 22C
0.68
-
alanine-4-nitroanilide
-
pH 8.0, 37C
1.3
-
Arg-Ser-Arg
-
wild type enzyme, 500 mM KCl in 250 mM Tris buffer (pH 7.5)
0.2
-
arginine-4-nitroanilide
-
pH 7.6, 22C
1.9
-
L-Ala-p-nitroanilide
-
mutant enzyme E296Q, 500 mM KCl in 250 mM Tris buffer (pH 7.5); wild type enzyme, 500 mM KCl in 250 mM Tris buffer (pH 7.5)
3
-
L-Ala-p-nitroanilide
-
mutant enzyme D375A, 500 mM KCl in 250 mM Tris buffer (pH 7.5)
0.31
-
L-alanine 2-naphthylamide
-
mutant N362L, 25C, pH not specified in the publication
-
0.339
-
L-alanine 2-naphthylamide
-
mutant W365L, 25C, pH not specified in the publication
-
0.4
-
L-alanine 2-naphthylamide
-
mutant N362Q, 25C, pH not specified in the publication
-
0.618
-
L-alanine 2-naphthylamide
-
mutant N362E, 25C, pH not specified in the publication
-
0.885
-
L-alanine 2-naphthylamide
-
mutant D399A, 25C, pH not specified in the publication
-
1.78
-
L-alanine 2-naphthylamide
-
wild-type, 25C, pH not specified in the publication
-
10.8
-
L-alanine-4-nitroanilide
-
-
1.5
-
L-Arg-p-nitroanilide
-
wild type enzyme, 500 mM KCl in 250 mM Tris buffer (pH 7.5)
2.2
-
L-Arg-p-nitroanilide
-
mutant enzyme E296Q, 500 mM KCl in 250 mM Tris buffer (pH 7.5)
0.137
-
L-arginine 2-naphthylamide
-
mutant N362Q, 25C, pH not specified in the publication
-
0.199
-
L-arginine 2-naphthylamide
-
mutant D399A, 25C, pH not specified in the publication
-
0.275
-
L-arginine 2-naphthylamide
-
mutant W365L, 25C, pH not specified in the publication
-
0.366
-
L-arginine 2-naphthylamide
-
wild-type, 25C, pH not specified in the publication
-
0.49
-
L-arginine 2-naphthylamide
-
mutant N362L, 25C, pH not specified in the publication
-
0.587
-
L-arginine 2-naphthylamide
-
mutant N362E, 25C, pH not specified in the publication
-
0.488
-
L-isoleucine 2-naphthylamide
-
mutant W365L, 25C, pH not specified in the publication
-
0.566
-
L-isoleucine 2-naphthylamide
-
wild-type, 25C, pH not specified in the publication
-
0.657
-
L-isoleucine 2-naphthylamide
-
mutant D399A, 25C, pH not specified in the publication
-
0.698
-
L-isoleucine 2-naphthylamide
-
mutant N362Q, 25C, pH not specified in the publication
-
0.105
-
L-leucine 2-naphthylamide
-
mutant N362Q, 25C, pH not specified in the publication
-
0.29
-
L-leucine 2-naphthylamide
-
mutant N362L, 25C, pH not specified in the publication
-
0.365
-
L-leucine 2-naphthylamide
-
mutant N362E, 25C, pH not specified in the publication
-
0.693
-
L-leucine 2-naphthylamide
-
mutant D399A, 25C, pH not specified in the publication
-
0.745
-
L-leucine 2-naphthylamide
-
wild-type, 25C, pH not specified in the publication
-
0.771
-
L-leucine 2-naphthylamide
-
mutant W365L, 25C, pH not specified in the publication
-
0.128
-
L-methionine 2-naphthylamide
-
mutant N362L, 25C, pH not specified in the publication
-
0.15
-
L-methionine 2-naphthylamide
-
mutant N362Q, 25C, pH not specified in the publication
-
0.166
-
L-methionine 2-naphthylamide
-
mutant N362E, 25C, pH not specified in the publication
-
0.351
-
L-methionine 2-naphthylamide
-
mutant W365L, 25C, pH not specified in the publication
-
0.374
-
L-methionine 2-naphthylamide
-
mutant D399A, 25C, pH not specified in the publication
-
0.7
-
L-methionine 2-naphthylamide
-
wild-type, 25C, pH not specified in the publication
-
0.235
-
L-valine 2-naphthylamide
-
mutant N362Q, 25C, pH not specified in the publication
-
0.384
-
L-valine 2-naphthylamide
-
wild-type, 25C, pH not specified in the publication
-
0.803
-
L-valine 2-naphthylamide
-
mutant D399A, 25C, pH not specified in the publication
-
0.808
-
L-valine 2-naphthylamide
-
mutant W365L, 25C, pH not specified in the publication
-
0.15
-
leucine-4-nitroanilide
-
pH 7.5, 22C
0.3
-
leucine-4-nitroanilide
-
pH 7.6, 22C
1.5
-
leucine-4-nitroanilide
-
pH 7.5, 22C
2
-
leucine-4-nitroanilide
-
pH 7.5, 22C, enzyme stimulated by leukotriene A4
2.1
-
leucine-4-nitroanilide
-
pH 7.5, 22C, enzyme stimulated by leukotriene A4
0.001
0.005
leukotriene A4
-
pH 7.9, 22C, mutant E296D
0.0027
-
leukotriene A4
-
pH 8.0, 22C
0.005
-
leukotriene A4
-
pH 8.0, 0C
0.005
-
leukotriene A4
-
pH 7.9, 22C, mutant E296N; pH 7.9, 22C, wild-type enzyme
0.006
0.028
leukotriene A4
-
pH 8.0, wild-type enzyme in comparison to mutant enzymes
0.006
-
leukotriene A4
-
pH 8.0, 22C, wild-type enzyme
0.011
-
leukotriene A4
-
pH 7.9, 22C, mutant E296Q
0.013
0.014
leukotriene A4
-
pH 7.8, 37C
0.017
-
leukotriene A4
-
pH 7.8, 37C
0.02
0.03
leukotriene A4
-
pH 7.7-7.8, 37C
0.02
0.03
leukotriene A4
-
pH 7.7-7.8, 37C
0.02
-
leukotriene A4
-
pH 8.0, 22C
0.022
-
leukotriene A4
-
pH 7.7-8.0, 2C
0.023
-
leukotriene A4
-
pH 7.7-8.0, 37C
0.023
-
leukotriene A4
-
pH 8.0, 22C, mutant Y378F
0.027
-
leukotriene A4
-
pH 8.0, 37C
0.06
-
leukotriene A4
-
pH 7.5, 22C, 5S,6S-dihydroxy-7,9-trans-11,14-cis-eicosatetraenoic acid production
0.1
-
proline-4-nitroanilide
-
pH 7.6, 22C
0.1
-
lysine-4-nitroanilide
-
pH 7.6, 22C
additional information
-
additional information
-
-
-
additional information
-
additional information
-
-
-
additional information
-
additional information
-
influence of NaCl and NaSCN on KM
-
additional information
-
additional information
-
-
-
additional information
-
additional information
-
-
-
additional information
-
additional information
-
-
-
TURNOVER NUMBER [1/s]
TURNOVER NUMBER MAXIMUM[1/s]
SUBSTRATE
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
IMAGE
0.6
-
alanine-4-nitroanilide
-
pH 7.6, 22C
0.56
-
Arg-Ser-Arg
-
wild type enzyme, 500 mM KCl in 250 mM Tris buffer (pH 7.5)
0.15
-
arginine-4-nitroanilide
-
pH 7.6, 22C
0.001
-
L-Ala-p-nitroanilide
-
mutant enzyme E296Q, 500 mM KCl in 250 mM Tris buffer (pH 7.5)
0.5
-
L-Ala-p-nitroanilide
-
mutant enzyme D375A, 500 mM KCl in 250 mM Tris buffer (pH 7.5)
1.7
-
L-Ala-p-nitroanilide
-
wild type enzyme, 500 mM KCl in 250 mM Tris buffer (pH 7.5)
0.0005
-
L-alanine 2-naphthylamide
-
mutant N362L, 25C, pH not specified in the publication
-
0.003
-
L-alanine 2-naphthylamide
-
mutant N362E, 25C, pH not specified in the publication
-
0.013
-
L-alanine 2-naphthylamide
-
mutant N362Q, 25C, pH not specified in the publication
-
0.03
-
L-alanine 2-naphthylamide
-
wild-type, 25C, pH not specified in the publication
-
0.065
-
L-alanine 2-naphthylamide
-
mutant D399A, 25C, pH not specified in the publication
-
0.109
-
L-alanine 2-naphthylamide
-
mutant W365L, 25C, pH not specified in the publication
-
1.9
-
L-alanine-4-nitroanilide
-
-
0.002
-
L-Arg-p-nitroanilide
-
mutant enzyme E296Q, 500 mM KCl in 250 mM Tris buffer (pH 7.5)
1.9
-
L-Arg-p-nitroanilide
-
wild type enzyme, 500 mM KCl in 250 mM Tris buffer (pH 7.5)
0.0003
-
L-arginine 2-naphthylamide
-
mutant N362L, 25C, pH not specified in the publication
-
0.005
-
L-arginine 2-naphthylamide
-
mutant N362E, 25C, pH not specified in the publication
-
0.012
-
L-arginine 2-naphthylamide
-
mutant N362Q, 25C, pH not specified in the publication
-
0.02
-
L-arginine 2-naphthylamide
-
mutant D399A, 25C, pH not specified in the publication; wild-type, 25C, pH not specified in the publication
-
0.039
-
L-arginine 2-naphthylamide
-
mutant W365L, 25C, pH not specified in the publication
-
0.009
-
L-isoleucine 2-naphthylamide
-
mutant N362Q, 25C, pH not specified in the publication
-
0.01
-
L-isoleucine 2-naphthylamide
-
wild-type, 25C, pH not specified in the publication
-
0.017
-
L-isoleucine 2-naphthylamide
-
mutant D399A, 25C, pH not specified in the publication
-
0.027
-
L-isoleucine 2-naphthylamide
-
mutant W365L, 25C, pH not specified in the publication
-
0.001
-
L-leucine 2-naphthylamide
-
mutant N362L, 25C, pH not specified in the publication
-
0.006
-
L-leucine 2-naphthylamide
-
mutant N362Q, 25C, pH not specified in the publication
-
0.007
-
L-leucine 2-naphthylamide
-
mutant N362E, 25C, pH not specified in the publication
-
0.15
-
L-leucine 2-naphthylamide
-
wild-type, 25C, pH not specified in the publication
-
0.17
-
L-leucine 2-naphthylamide
-
mutant D399A, 25C, pH not specified in the publication
-
0.225
-
L-leucine 2-naphthylamide
-
mutant W365L, 25C, pH not specified in the publication
-
0.003
-
L-methionine 2-naphthylamide
-
mutant N362L, 25C, pH not specified in the publication
-
0.009
-
L-methionine 2-naphthylamide
-
mutant N362E, 25C, pH not specified in the publication
-
0.027
-
L-methionine 2-naphthylamide
-
mutant N362Q, 25C, pH not specified in the publication
-
0.098
-
L-methionine 2-naphthylamide
-
mutant D399A, 25C, pH not specified in the publication
-
0.15
-
L-methionine 2-naphthylamide
-
wild-type, 25C, pH not specified in the publication
-
0.159
-
L-methionine 2-naphthylamide
-
mutant W365L, 25C, pH not specified in the publication
-
0.004
-
L-valine 2-naphthylamide
-
mutant N362Q, 25C, pH not specified in the publication
-
0.02
-
L-valine 2-naphthylamide
-
mutant D399A, 25C, pH not specified in the publication; wild-type, 25C, pH not specified in the publication
-
0.034
-
L-valine 2-naphthylamide
-
mutant W365L, 25C, pH not specified in the publication
-
0.15
-
leucine-4-nitroanilide
-
pH 7.6, 22C
0.35
-
leucine-4-nitroanilide
-
pH 7.5, 22C
0.63
-
leucine-4-nitroanilide
-
pH 7.5, 22C
5.2
-
leucine-4-nitroanilide
-
pH 7.5, 22C, enzyme stimulated by leukotriene A4
0.15
2.4
leukotriene A4
-
value depending on NaSCN concentration
0.21
0.47
leukotriene A4
-
pH 8.0, wild-type enzyme in comparison to mutant enzymes
0.7
-
leukotriene A4
-
-
0.85
-
leukotriene A4
-
pH 8.0, 22C, wild-type enzyme
0.9
-
leukotriene A4
-
pH 7.9, 22C, wild-type enzyme
1.4
-
leukotriene A4
-
pH 7.9, 22C, mutant E296Q
1.5
-
leukotriene A4
-
pH 8.0, 22C
2.08
-
leukotriene A4
-
pH 7.7-8.0, 37C
2.09
-
leukotriene A4
-
pH 8.0, 22C, mutant Y378F
14
-
leukotriene A4
-
pH 8.0, 22C
0.15
-
proline-4-nitroanilide
-
pH 7.6, 22C
0.04
-
lysine-4-nitroanilide
-
pH 7.6, 22C
additional information
-
additional information
-
-
-
additional information
-
additional information
-
-
-
kcat/KM VALUE [1/mMs-1]
kcat/KM VALUE [1/mMs-1] Maximum
SUBSTRATE
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
IMAGE
0.002
-
L-alanine 2-naphthylamide
-
mutant N362L, 25C, pH not specified in the publication
0
0.005
-
L-alanine 2-naphthylamide
-
mutant N362E, 25C, pH not specified in the publication
0
0.01
-
L-alanine 2-naphthylamide
-
wild-type, 25C, pH not specified in the publication
0
0.032
-
L-alanine 2-naphthylamide
-
mutant N362Q, 25C, pH not specified in the publication
0
0.073
-
L-alanine 2-naphthylamide
-
mutant D399A, 25C, pH not specified in the publication
0
0.321
-
L-alanine 2-naphthylamide
-
mutant W365L, 25C, pH not specified in the publication
0
0.001
-
L-arginine 2-naphthylamide
-
mutant N362L, 25C, pH not specified in the publication
0
0.009
-
L-arginine 2-naphthylamide
-
mutant N362E, 25C, pH not specified in the publication
0
0.04
-
L-arginine 2-naphthylamide
-
wild-type, 25C, pH not specified in the publication
0
0.09
-
L-arginine 2-naphthylamide
-
mutant N362Q, 25C, pH not specified in the publication
0
0.117
-
L-arginine 2-naphthylamide
-
mutant D399A, 25C, pH not specified in the publication
0
0.141
-
L-arginine 2-naphthylamide
-
mutant W365L, 25C, pH not specified in the publication
0
0.012
-
L-isoleucine 2-naphthylamide
-
mutant N362Q, 25C, pH not specified in the publication
0
0.026
-
L-isoleucine 2-naphthylamide
-
mutant D399A, 25C, pH not specified in the publication
0
0.03
-
L-isoleucine 2-naphthylamide
-
wild-type, 25C, pH not specified in the publication
0
0.055
-
L-isoleucine 2-naphthylamide
-
mutant W365L, 25C, pH not specified in the publication
0
0.005
-
L-leucine 2-naphthylamide
-
mutant N362L, 25C, pH not specified in the publication
0
0.018
-
L-leucine 2-naphthylamide
-
mutant N362E, 25C, pH not specified in the publication
0
0.057
-
L-leucine 2-naphthylamide
-
mutant N362Q, 25C, pH not specified in the publication
0
0.2
-
L-leucine 2-naphthylamide
-
wild-type, 25C, pH not specified in the publication
0
0.238
-
L-leucine 2-naphthylamide
-
mutant D399A, 25C, pH not specified in the publication
0
0.292
-
L-leucine 2-naphthylamide
-
mutant W365L, 25C, pH not specified in the publication
0
0.025
-
L-methionine 2-naphthylamide
-
mutant N362L, 25C, pH not specified in the publication
0
0.052
-
L-methionine 2-naphthylamide
-
mutant N362E, 25C, pH not specified in the publication
0
0.177
-
L-methionine 2-naphthylamide
-
mutant N362Q, 25C, pH not specified in the publication
0
0.21
-
L-methionine 2-naphthylamide
-
wild-type, 25C, pH not specified in the publication
0
0.263
-
L-methionine 2-naphthylamide
-
mutant D399A, 25C, pH not specified in the publication
0
0.453
-
L-methionine 2-naphthylamide
-
mutant W365L, 25C, pH not specified in the publication
0
0.016
-
L-valine 2-naphthylamide
-
mutant N362Q, 25C, pH not specified in the publication
0
0.03
-
L-valine 2-naphthylamide
-
mutant D399A, 25C, pH not specified in the publication
0
0.042
-
L-valine 2-naphthylamide
-
mutant W365L, 25C, pH not specified in the publication
0
0.05
-
L-valine 2-naphthylamide
-
wild-type, 25C, pH not specified in the publication
0
Ki VALUE [mM]
Ki VALUE [mM] Maximum
INHIBITOR
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
IMAGE
0.0003
-
1,10-phenanthroline
-
pH 8.0, 22C
0.046
-
2-oxo-3-amino carboxylic ester
-
-
-
0.006
-
3-amino-3,4-dihydro-1H-naphthalen-2-one O-(3-phenylpropyl)oxime
-
-
0.008
-
3-amino-3,4-dihydro-1H-naphthalen-2-one O-(4-phenylbutyl)oxime
-
-
0.03
-
3-amino-3,4-dihydro-1H-naphthalen-2-one O-(5-phenylpentyl)oxime
-
-
0.0002
-
bestatin
-
pH 8.0, 37C
0.0007
-
bestatin
-
pH 7.9, 22C, wild-type enzyme
0.0024
-
bestatin
-
mutant W365L, 25C, pH not specified in the publication
0.0027
-
bestatin
-
wild-type LTA4H
0.0032
-
bestatin
-
mutant N362E, 25C, pH not specified in the publication
0.0036
-
bestatin
-
mutant N362Q, 25C, pH not specified in the publication
0.004
-
bestatin
-
mutant N362L, 25C, pH not specified in the publication
0.0046
-
bestatin
-
wild-type, 25C, pH not specified in the publication
0.008
-
bestatin
-
mutant D399A, 25C, pH not specified in the publication
0.021
-
bestatin
-
pH 7.9, 22C, mutant E296Q
0.049
-
bestatin
-
mutant Y456F
0.0765
-
bestatin
-
mutant Y244F
0.0005
-
HgCl2
-
pH 7.8, 37C
3
-
NEM
-
pH 7.8, 37C
0.0007
-
PCMB
-
pH 7.8, 37C
1.33
-
puromycin
-
mutant N362Q, 25C, pH not specified in the publication
2.37
-
puromycin
-
mutant Y244F
2.82
-
puromycin
-
mutant W365L, 25C, pH not specified in the publication
3.16
-
puromycin
-
wild-type LTA4H
3.24
-
puromycin
-
mutant Y456F
4.16
-
puromycin
-
wild-type, 25C, pH not specified in the publication
4.39
-
puromycin
-
mutant D399A, 25C, pH not specified in the publication
5.1
-
puromycin
-
mutant N362L, 25C, pH not specified in the publication
5.6
-
puromycin
-
mutant N362E, 25C, pH not specified in the publication
8.7e-05
-
RB-3014
-
wild-type LTA4H
-
0.00074
-
RB-3014
-
mutant Y456F
-
0.0037
-
RB-3014
-
mutant Y244F
-
0.005
-
leukotriene A4
-
pH 8.0, 37C
additional information
-
additional information
-
-
-
additional information
-
additional information
-
-
-
additional information
-
additional information
-
-
-
IC50 VALUE [mM]
IC50 VALUE [mM] Maximum
INHIBITOR
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
IMAGE
1.4e-05
-
(1-[2-[4-(benzooxazol-2-yloxy)phenoxy]ethyl]piperidin-4-yl)methanol
-
-
1.3e-05
-
(1-[2-[4-(benzothiazol-2-yloxy)phenoxy]ethyl]piperidin-4-yl)-methanol
-
-
5.6e-05
-
(2R)-2-([4-[4-(thiophen-2-yl)benzyl]phenoxy]methyl)piperidine
-
-
-
6e-05
-
(2R)-2-([4-[4-(thiophen-3-yl)benzyl]phenoxy]methyl)piperidine
-
-
-
9.3e-05
-
(2R)-2-([4-[4-(thiophen-3-yl)phenoxy]phenoxy]methyl)piperidine
-
-
-
4.4e-05
-
(2R)-2-[(4-phenoxyphenoxy)methyl]piperidine
-
-
0.0049
-
(2R)-2-[[(2S)-2-methyl-3-sulfanylpropanoyl]amino]-3-[(4-nitrobenzyl)sulfanyl]propanoic acid
-
-
0.0017
-
(2R)-2-[[(2S)-2-methyl-3-sulfanylpropanoyl]amino]-3-[(4-phenoxybenzyl)sulfanyl]propanoic acid
-
-
7.2e-05
-
(2R)-2-[[(2S)-2-methyl-3-sulfanylpropanoyl]amino]-3-[(4-propylbenzyl)sulfanyl]propanoic acid
-
-
0.0004
-
(2R)-2-[[(2S)-2-methyl-3-sulfanylpropanoyl]amino]-3-[[4-(trifluoromethoxy)benzyl]sulfanyl]propanoic acid
-
-
0.00014
-
(2R)-2-[[(2S)-2-methyl-3-sulfanylpropanoyl]amino]-3-[[4-(trifluoromethyl)benzyl]sulfanyl]propanoic acid
-
-
0.000438
-
(2R)-2-[[4-(4-chlorobenzyl)phenoxy]methyl]piperidine
-
-
-
6.9e-06
-
(2R)-2-[[4-(4-chlorophenoxy)phenoxy]methyl]-1-(1,2,4-oxadiazol-2(3H)-ylmethyl)piperidine
-
-
-
0.00011
-
(2R)-2-[[4-(4-chlorophenoxy)phenoxy]methyl]piperidine
-
-
-
0.000174
-
(2R)-2-[[4-(4-fluorophenoxy)phenoxy]methyl]piperidine
-
-
0.000114
-
(2R)-2-[[4-(biphenyl-4-yloxy)phenoxy]methyl]piperidine
-
-
0.01
-
(2R)-3-(benzylsulfanyl)-2-[[(2S)-2-methyl-3-sulfanylpropanoyl]amino]propanoic acid
-
IC50 above 0.01 mM
0.00061
-
(2R)-3-[(4-bromobenzyl)sulfanyl]-2-[[(2S)-2-methyl-3-sulfanylpropanoyl]amino]propanoic acid
-
-
0.0017
-
(2R)-3-[(4-chlorobenzyl)sulfanyl]-2-[[(2S)-2-methyl-3-sulfanylpropanoyl]amino]propanoic acid
-
-
0.00053
-
(2R)-3-[(4-cyanobenzyl)sulfanyl]-2-[[(2S)-2-methyl-3-sulfanylpropanoyl]amino]propanoic acid
-
-
0.00064
-
(2R)-3-[(4-ethoxybenzyl)sulfanyl]-2-[[(2S)-2-methyl-3-sulfanylpropanoyl]amino]propanoic acid
-
-
0.00028
-
(2R)-3-[(4-ethylbenzyl)sulfanyl]-2-[[(2S)-2-methyl-3-sulfanylpropanoyl]amino]propanoic acid
-
-
0.01
-
(2R)-3-[(4-fluorobenzyl)sulfanyl]-2-[[(2S)-2-methyl-3-sulfanylpropanoyl]amino]propanoic acid
-
IC50 above 0.01 mM
1.5e-05
-
(2R)-3-[(4-iodobenzyl)sulfanyl]-2-[[(2S)-2-methyl-3-sulfanylpropanoyl]amino]propanoic acid
-
-
0.0024
-
(2R)-3-[(4-methoxybenzyl)sulfanyl]-2-[[(2S)-2-methyl-3-sulfanylpropanoyl]amino]propanoic acid
-
-
0.0072
-
(2R)-3-[(4-methylbenzyl)sulfanyl]-2-[[(2S)-2-methyl-3-sulfanylpropanoyl]amino]propanoic acid
-
-
0.0006
-
(2R)-3-[(biphenyl-4-ylmethyl)sulfanyl]-2-[[(2S)-2-methyl-3-sulfanylpropanoyl]amino]propanoic acid
-
-
0.01
-
(2R)-3-[[3-(dimethylamino)benzyl]sulfanyl]-2-[[(2S)-2-methyl-3-sulfanylpropanoyl]amino]propanoic acid
-
IC50 above 0.01 mM
0.0002
-
(2R)-3-[[4-(1-methylethyl)benzyl]sulfanyl]-2-[[(2S)-2-methyl-3-sulfanylpropanoyl]amino]propanoic acid
-
-
0.0074
-
(2R)-3-[[4-(dimethylamino)benzyl]sulfanyl]-2-[(3-sulfanylbutanoyl)amino]propanoic acid
-
-
0.01
-
(2R)-3-[[4-(dimethylamino)benzyl]sulfanyl]-2-[(3-sulfanylpropanoyl)amino]propanoic acid
-
IC50 above 0.01 mM
0.01
-
(2R)-3-[[4-(dimethylamino)benzyl]sulfanyl]-2-[(4-sulfanylbutanoyl)amino]propanoic acid
-
IC50 above 0.01 mM
0.00047
-
(2R)-3-[[4-(dimethylamino)benzyl]sulfanyl]-2-[(sulfanylacetyl)amino]propanoic acid
-
-
0.0015
-
(2R)-3-[[4-(dimethylamino)benzyl]sulfanyl]-2-[[(2R)-2-methyl-3-sulfanylpropanoyl]amino]propanoic acid
-
-
0.01
-
(2R)-3-[[4-(dimethylamino)benzyl]sulfanyl]-2-[[(2R)-2-sulfanylpropanoyl]amino]propanoic acid
-
IC50 above 0.01 mM
0.00027
-
(2R)-3-[[4-(dimethylamino)benzyl]sulfanyl]-2-[[(2S)-2-methyl-3-sulfanylpropanoyl]amino]propanoic acid
-
-
0.01
-
(2R)-3-[[4-(dimethylamino)benzyl]sulfanyl]-2-[[(2S)-2-sulfanylpropanoyl]amino]propanoic acid
-
IC50 above 0.01 mM
0.00016
-
(2R)-3-[[4-(methoxysulfinyl)benzyl]sulfanyl]-2-[[(2S)-2-methyl-3-sulfanylpropanoyl]amino]propanoic acid
-
-
4.6e-05
-
(2R)-3-[[4-(methylsulfanyl)benzyl]sulfanyl]-2-[[(2S)-2-methyl-3-sulfanylpropanoyl]amino]propanoic acid
-
-
0.0058
-
(2S)-2,6-diamino-N-[4-(phenylmethoxy)phenyl]hexanamide dihydrochloride
-
-
9.3e-05
-
(2S)-2-([4-[4-(trifluoromethyl)phenoxy]phenoxy]methyl)piperidine
-
-
0.00013
-
(2S)-2-amino-5-oxo-5-[(4-phenoxyphenyl)amino]-1-pentanesulfonic acid
-
-
0.01
-
(2S)-2-amino-N-[4-(phenylmethoxy)phenyl]-3-[4-(1H-imidazole)]propanamide dihydrochloride
-
-
0.00015
-
(2S)-2-amino-N-[4-(phenylmethoxy)phenyl]-propanamide hydrochloride
-
-
0.002
-
(2S)-2-amino-N-[4-(phenylmethoxy)phenyl]benzenepropanamide hydrochloride
-
IC50 above 0.002 mM
9.4e-05
-
(2S)-2-[(4-benzylphenoxy)methyl]piperidine
-
-
-
4.8e-05
-
(2S)-2-[(4-phenoxyphenoxy)methyl]piperidine
-
-
0.000315
-
(2S)-2-[[4-(4-chlorobenzyl)phenoxy]methyl]piperidine
-
-
-
9.6e-05
-
(2S)-2-[[4-(biphenyl-4-yloxy)phenoxy]methyl]piperidine
-
-
0.01
-
(2S)-3-[[4-(dimethylamino)benzyl]sulfanyl]-2-[[(2S)-2-methyl-3-sulfanylpropanoyl]amino]propanoic acid
-
IC50 above 0.01 mM
0.01
-
(2S)-4-[[4-(dimethylamino)benzyl]sulfanyl]-2-[[(2S)-2-methyl-3-sulfanylpropanoyl]amino]butanoic acid
-
IC50 above 0.01 mM
0.002
-
(2S)-N-[4-(phenylmethoxy)phenyl]-2-pyrrolidinecarboxamide hydrochloride
-
IC50 above 0.002 mM
0.002
-
(2S,3S)-2-amino-3-methyl-N-[4-(phenylmethoxy)-phenyl]pentanamide
-
IC50 above 0.002 mM
0.0051
-
(2S,4S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]-4-[(2-phenylethyl)sulfanyl]pyrrolidine-2-carboxylic acid
-
-
0.0011
-
(2S,4S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]-4-[(3-phenylpropyl)sulfanyl]pyrrolidine-2-carboxylic acid
-
-
0.0092
-
(2S,4S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]-4-[(naphthalen-1-ylmethyl)sulfanyl]pyrrolidine-2-carboxylic acid
-
-
0.0011
-
(2S,4S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]-4-[(naphthalen-2-ylmethyl)sulfanyl]pyrrolidine-2-carboxylic acid
-
-
0.0036
-
(2S,4S)-4-(benzylsulfanyl)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid
-
-
0.00084
-
(2S,4S)-4-[(2-methylbenzyl)sulfanyl]-1-[(2S)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid
-
-
0.01
-
(2S,4S)-4-[(3-methylbenzyl)sulfanyl]-1-[(2S)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid
-
IC50 above 0.01 mM
0.00012
-
(2S,4S)-4-[[4-(methylsulfanyl)benzyl]sulfanyl]-1-[(2S)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid
-
-
0.00029
-
(4R)-4-[[4-(1-methylethyl)benzyl]sulfanyl]-1-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-proline
-
-
2.1e-05
-
(4S)-4,5-diamino-N-(4-phenoxyphenyl)pentanamide
-
-
0.00079
-
(4S)-4-([2-[4-(1-methylethyl)phenyl]ethyl]sulfanyl)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-proline
-
-
0.0027
-
(4S)-4-([3-[4-(1-methylethyl)phenyl]propyl]sulfanyl)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-proline
-
-
0.00074
-
(4S)-4-amino-4-(2-(1,3,4-triazolyl))-N-(4-phenoxyphenyl)butanamide trifluoroacetate
-
-
8.5e-05
-
(4S)-4-amino-5-(1-phthalimido)-N-(4-phenoxyphenyl)pentanamide trifluoroacetate
-
-
0.00039
-
(4S)-4-amino-5-(1H-pyrrol-1-yl)-N-(4-phenoxyphenyl)pentanamide bistrifluoroacetate
-
-
0.00035
-
(4S)-4-amino-5-(2-thio-5-amino-1,3,4-thiadiazol-2-yl)-N-(4-phenoxyphenyl)pentanamide bistrifluoroacetate
-
-
1.4e-05
-
(4S)-4-amino-5-hydroxy-N-(4-phenoxyphenyl)pentanamide
-
-
0.0056
-
(4S)-4-amino-5-methoxy-N-(4-phenoxyphenyl)-pentanamide
-
-
3.4e-05
-
(4S)-4-[(4-cyclohexylbenzyl)sulfanyl]-1-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-proline
-
-
3.1e-05
-
(4S)-4-[(4-tert-butylbenzyl)sulfanyl]-1-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-proline
-
-
5.2e-05
-
(4S)-4-[[4-(1-methylethyl)benzyl]sulfanyl]-1-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-proline
-
-
8.7e-05
-
(R)-2-(4-benzylphenoxymethyl)pyrrolidine
-
-
3e-05
-
(R)-2-[4-(4-chlorophenoxy)phenoxymethyl]pyrrolidine
-
-
7e-05
-
1'-[2-[4-(benzothiazol-2-yloxy)phenoxy]ethyl][1,4']bipiperidinyl-2-one
-
-
1.6e-05
-
1-(1-[2-[4-(benzothiazol-2-yloxy)phenoxy]ethyl]piperidin-4-yl)pyrrolidin-2-one
-
-
1.3e-05
-
1-(1-[2-[4-(benzothiazol-2-yloxy)phenyl]ethyl]piperidin-4-yl)pyrrolidin-2-one
-
-
0.00022
-
1-(2-(4-(2-(trifluoromethyl)phenoxy)phenoxy)ethyl)pyrrolidine
-
pH 7.4, 37C
-
0.00068
-
1-(2-(4-(2-nitrophenoxy)phenoxy)ethyl)pyrrolidine
-
pH 7.4, 37C
-
4e-05
-
1-(2-(4-(4-chlorophenoxy)phenoxy)ethyl)pyrrolidine
-
pH 7.4, 37C
-
8e-05
-
1-(2-(4-(4-fluorophenoxy)phenoxy)ethyl)pyrrolidine
-
pH 7.4, 37C
-
0.00037
-
1-(2-(4-(4-nitrophenoxy)phenoxy)ethyl)pyrrolidine
-
pH 7.4, 37C
-
3e-05
-
1-(2-(4-phenoxyphenoxy)ethyl)pyrrolidine
-
pH 7.4, 37C
-
0.00066
-
1-benzyl-3-[(4-benzylphenoxy)methyl]piperazine
-
-
-
1.2e-05
-
1-[1-[4-(benzothiazol-2-yloxy)benzyl]piperidin-4-yl]pyrrolidin-2-one
-
-
6e-06
-
1-[2-[4-(benzooxazol-2-yloxy)phenoxy]ethyl]-4-phenylpiperidin-4-ol
-
-
9e-06
-
1-[2-[4-(benzooxazol-2-yloxy)phenoxy]ethyl]piperidin-4-ol
-
-
6.6e-05
-
1-[2-[4-(benzothiazol-2-yloxy)phenoxy]ethyl]-4-phenylpiperidin-4-ol
-
-
3.1e-05
-
1-[2-[4-(benzothiazol-2-yloxy)phenoxy]ethyl]piperidin-4-ol
-
-
1.3e-05
-
1-[2-[4-(benzothiazol-2-yloxy)phenoxy]ethyl]piperidine-4-carboxylic acid amide
-
-
8e-06
-
1-[2-[4-(benzothiazol-2-yloxy)phenyl]ethyl]piperidin-4-ol
-
-
2.8e-05
-
1-[2-[4-(benzothiazol-2-yloxy)phenyl]ethyl]piperidine-4-carboxylic acid amide
-
-
3.4e-05
-
1-[4-(benzothiazol-2-yloxy)benzyl]piperidin-4-ol
-
-
1.1e-05
-
1-[4-(benzothiazol-2-yloxy)benzyl]piperidine-4-carboxylic acid
-
-
1.7e-05
-
1-[4-(benzothiazol-2-yloxy)benzyl]piperidine-4-carboxylic acid amide
-
-
5.9e-05
-
2-(4-piperidin-1-ylmethylphenoxy)benzothiazole
-
-
0.00028
-
2-amino-N-[4-(phenylmethoxy)phenyl]-acetamide
-
-
1e-05
-
2-bromo-4-[(methyl[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]amino)methyl]benzoic acid
-
-
6e-06
-
2-fluoro-4-[(methyl[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]amino)methyl]benzoic acid
-
-
0.000342
-
2-[(4-benzylphenoxy)methyl]piperazine
-
-
0.000134
-
2-[(4-benzylphenoxy)methyl]piperidine
-
-
7e-05
-
2-[(4-phenoxyphenoxy)methyl]piperidine
-
-
-
0.00014
-
2-[4-(2-azepan-1-ylethoxy)phenoxy]-1H-benzoimidazole
-
-
4e-06
-
2-[4-(2-azepan-1-ylethoxy)phenoxy]benzooxazole
-
-
6.6e-05
-
2-[4-(2-azepan-1-ylethoxy)phenoxy]benzothiazole
-
-
0.003
-
2-[4-(2-morpholin-4-ylethoxy)phenoxy]-1H-benzoimidazole
-
-
5.8e-05
-
2-[4-(2-morpholin-4-ylethoxy)phenoxy]benzooxazole
-
-
0.00035
-
2-[4-(2-morpholin-4-ylethoxy)phenoxy]benzothiazole
-
-
0.00011
-
2-[4-(2-piperidin-1-ylethoxy)phenoxy]-1H-benzoimidazole
-
-
1.1e-05
-
2-[4-(2-piperidin-1-ylethoxy)phenoxy]benzooxazole
-
-
5.4e-05
-
2-[4-(2-piperidin-1-ylethoxy)phenoxy]benzothiazole
-
-
1.7e-05
-
2-[4-(2-piperidin-1-ylethyl)phenoxy]benzothiazole
-
-
8.4e-05
-
2-[4-(2-pyrrolidin-1-ylethoxy)phenoxy]-1H-benzoimidazole
-
-
7e-06
-
2-[4-(2-pyrrolidin-1-ylethoxy)phenoxy]benzooxazole
-
-
1.4e-05
-
2-[4-(2-pyrrolidin-1-ylethoxy)phenoxy]benzothiazole
-
-
1.1e-05
-
3-(1-[2-[4-(benzothiazol-2-yloxy)phenoxy]ethyl]piperidin-4-yl)oxazolidin-2-one
-
-
2.9e-05
-
3-(1-[2-[4-(benzothiazol-2-yloxy)phenyl]ethyl]piperidin-4-yl)oxazolidin-2-one
-
-
0.5
-
3-amino-3,4-dihydro-1H-naphthalen-2-one O-(2-phenylethyl)oxime
-
-
7e-06
-
3-fluoro-4-[(methyl[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]amino)methyl]benzoic acid
-
-
0.000212
-
3-[(2R)-2-[[4-(4-chlorophenoxy)phenoxy]methyl]piperidin-1-yl]propanoic acid
-
-
-
1e-05
-
3-[1-[4-(benzothiazol-2-yloxy)benzyl]piperidin-4-yl]oxazolidin-2-one
-
-
0.01
-
3-[[4-(1-methylethyl)benzyl]sulfanyl]-N-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-valine
-
IC50 above 0.01 mM
4.7e-05
-
4-((S)-2-[4-(4-chlorophenoxy)phenoxymethyl]pyrrolidin-1-yl)-butyric acid
-
-
3e-06
-
4-([(1R,5S)-3-[(4-benzylphenyl)amino]-8-azabicyclo[3.2.1]oct-8-yl]methyl)benzoic acid
-
-
1.4e-05
-
4-([(1R,5S)-3-[(4-phenoxyphenyl)amino]-8-azabicyclo[3.2.1]oct-8-yl]methyl)benzoic acid
-
-
7e-06
-
4-([2-[(methyl[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]amino)methyl]pyrrolidin-1-yl]methyl)benzoic acid
-
-
0.0001
-
4-([2-[(methyl[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]amino)methyl]pyrrolidin-1-yl]methyl)benzoic acid
-
-
5e-06
-
4-([4-[([4-[4-(1,3-oxazol-2-yl)phenoxy]phenyl]amino)methyl]piperidin-1-yl]methyl)benzoic acid
-
-
1.5e-05
-
4-([methyl[2-(methyl[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]amino)ethyl]amino]methyl)benzoic acid
-
-
0.00013
-
4-([methyl[2-([4-[4-(1,3-oxazol-2-yl)phenoxy]phenyl]amino)ethyl]amino]methyl)benzoic acid
-
-
0.00033
-
4-([methyl[3-([2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]amino)propyl]amino]methyl)benzoic acid
-
-
3e-06
-
4-([methyl[3-([4-[4-(1,3-oxazol-2-yl)phenoxy]phenyl]amino)propyl]amino]methyl)benzoic acid
-
-
9e-06
-
4-([methyl[4-([4-[4-(1,3-oxazol-2-yl)phenoxy]phenyl]amino)cyclohexyl]amino]methyl)benzoic acid
-
-
7e-06
-
4-([[2,2-dimethyl-3-(methyl[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]amino)propyl](methyl)amino]methyl)benzoic acid
-
-
1.9e-05
-
4-([[3-(methyl[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]amino)propyl]amino]methyl)benzoic acid
-
-
0.00037
-
4-([[3-([2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]amino)propyl]amino]methyl)benzoic acid
-
-
1.1e-05
-
4-([[4-([4-[4-(1,3-oxazol-2-yl)phenoxy]phenyl]amino)cyclohexyl]amino]methyl)benzoic acid
-
-
6.1e-05
-
4-amino-N-[4-(phenylmethoxy)phenyl]butanamide hydrochloride
-
-
0.0094
-
4-dimethylamino-N-[4-(phenylmethoxy)phenyl]-butanamide trifluoroacetate
-
-
0.011
-
4-methylamino-N-[4-(phenylmethoxy)phenyl]butanamide trifluoroacetate
-
-
0.000106
-
4-[(2R)-2-[[4-(4-chlorophenoxy)phenoxy]methyl]piperidin-1-yl]butanoic acid
-
-
4.9e-05
-
4-[(2S)-2-([4-[4-(thiophen-3-yl)benzyl]phenoxy]methyl)piperidin-1-yl]butanoic acid
-
-
5.3e-05
-
4-[(2S)-2-[[4-(4-chlorophenoxy)phenoxy]methyl]piperidin-1-yl]butanoic acid
-
-
-
7e-05
-
4-[(4-[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]-1,4-diazepan-1-yl)methyl]benzoic acid
-
-
0.001
-
4-[(4-[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]piperazin-1-yl)methyl]benzoic acid
-
-
4.4e-05
-
4-[(5-[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]-2,5-diazabicyclo[2.2.1]hept-2-yl)methyl]benzoic acid
-
-
1.5e-05
-
4-[(methyl[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]amino)methyl]-3-nitrobenzoic acid
-
-
6e-06
-
4-[(methyl[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]amino)methyl]benzoic acid
-
-
2.5e-05
-
4-[(methyl[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]amino)methyl]cyclohexanecarboxylic acid
-
-
1.6e-05
-
4-[(methyl[[(2R)-1-[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]piperidin-2-yl]methyl]amino)methyl]benzoic acid
-
-
2.6e-05
-
4-[(methyl[[(2R)-1-[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]pyrrolidin-2-yl]methyl]amino)methyl]benzoic acid
-
-
1.7e-05
-
4-[(methyl[[(2S)-1-[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]piperidin-2-yl]methyl]amino)methyl]benzoic acid
-
-
1.7e-05
-
4-[(methyl[[(2S)-1-[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]pyrrolidin-2-yl]methyl]amino)methyl]benzoic acid
-
-
3e-06
-
4-[2-(methyl[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]amino)ethyl]benzoic acid
-
-
1e-06
-
4-[2-[(1R,5S)-3-([4-[4-(1,3-oxazol-2-yl)phenoxy]phenyl]amino)-8-azabicyclo[3.2.1]oct-8-yl]ethyl]benzoic acid
-
-
2e-06
-
4-[2-[3-([4-[4-(1,3-oxazol-2-yl)phenoxy]phenyl]amino)piperidin-1-yl]ethyl]benzoic acid
-
-
3e-06
-
4-[2-[4-([4-[4-(1,3-oxazol-2-yl)phenoxy]phenyl]amino)piperidin-1-yl]ethyl]benzoic acid
-
-
5e-06
-
4-[[(1R,5S)-3-([4-[4-(1,3-oxazol-2-yl)phenoxy]phenyl]amino)-8-azabicyclo[3.2.1]oct-8-yl]methyl]benzoic acid
-
-
8e-06
-
4-[[(1R,5S)-3-([4-[4-(1,3-thiazol-2-yl)phenoxy]phenyl]amino)-8-azabicyclo[3.2.1]oct-8-yl]methyl]benzoic acid
-
-
4e-06
-
4-[[(1R,5S)-3-([4-[4-(1H-pyrrol-1-yl)phenoxy]phenyl]amino)-8-azabicyclo[3.2.1]oct-8-yl]methyl]benzoic acid
-
-
1.3e-05
-
4-[[(1R,5S)-3-([4-[4-(trifluoromethyl)phenoxy]phenyl]amino)-8-azabicyclo[3.2.1]oct-8-yl]methyl]benzoic acid
-
-
9e-06
-
4-[[(1R,5S)-3-[[4-(1,3-benzothiazol-2-yloxy)phenyl]amino]-8-azabicyclo[3.2.1]oct-8-yl]methyl]benzoic acid
-
-
0.00032
-
4-[[(1R,5S)-3-[[4-(2-chlorophenoxy)phenyl]amino]-8-azabicyclo[3.2.1]oct-8-yl]methyl]benzoic acid
-
-
6e-06
-
4-[[(1R,5S)-3-[[4-(2-fluorophenoxy)phenyl]amino]-8-azabicyclo[3.2.1]oct-8-yl]methyl]benzoic acid
-
-
6e-06
-
4-[[(1R,5S)-3-[[4-(4-chlorophenoxy)phenyl]amino]-8-azabicyclo[3.2.1]oct-8-yl]methyl]benzoic acid
-
-
4e-05
-
4-[[(1R,5S)-3-[[4-(4-fluorophenoxy)phenyl]amino]-8-azabicyclo[3.2.1]oct-8-yl]methyl]benzoic acid
-
-
2.3e-05
-
4-[[(1R,5S)-3-[[4-(4-methoxyphenoxy)phenyl]amino]-8-azabicyclo[3.2.1]oct-8-yl]methyl]benzoic acid
-
-
4.7e-05
-
4-[[(1R,5S)-3-[[4-(benzyloxy)phenyl]amino]-8-azabicyclo[3.2.1]oct-8-yl]methyl]benzoic acid
-
-
5e-06
-
4-[[(1R,5S)-3-[[4-(biphenyl-4-yloxy)phenyl]amino]-8-azabicyclo[3.2.1]oct-8-yl]methyl]benzoic acid
-
-
7.5e-05
-
4-[[(1R,5S)-3-[[4-(pyridin-4-ylmethyl)phenyl]amino]-8-azabicyclo[3.2.1]oct-8-yl]methyl]benzoic acid
-
-
1.9e-05
-
4-[[(3-[[2-([4-[(2R)-2-hydroxy-2-phenylethoxy]phenyl]amino)-2-oxoethyl](methyl)amino]propyl)(methyl)amino]methyl]benzoic acid
-
-
0.00012
-
4-[[(3R)-3-(methyl[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]amino)pyrrolidin-1-yl]methyl]benzoic acid
-
-
5.7e-05
-
4-[[(3S)-3-(methyl[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]amino)pyrrolidin-1-yl]methyl]benzoic acid
-
-
6e-05
-
4-[[3-([4-[4-(1,3-oxazol-2-yl)phenoxy]phenyl]amino)piperidin-1-yl]methyl]benzoic acid
-
-
7e-06
-
4-[[3-([4-[4-(1,3-oxazol-2-yl)phenoxy]phenyl]amino)pyrrolidin-1-yl]methyl]benzoic acid
-
-
6e-05
-
4-[[4-(1-[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]hydrazino)piperidin-1-yl]methyl]benzoic acid
-
-
0.00016
-
4-[[4-(methyl[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]amino)azepan-1-yl]methyl]benzoic acid
-
-
1.5e-05
-
4-[[4-([4-[4-(1,3-oxazol-2-yl)phenoxy]phenyl]amino)azepan-1-yl]methyl]benzoic acid
-
-
3e-05
-
4-[[4-([4-[4-(1,3-oxazol-2-yl)phenoxy]phenyl]amino)piperidin-1-yl]methyl]benzoic acid
-
-
0.00014
-
4-[[methyl(1-[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]azepan-4-yl)amino]methyl]benzoic acid
-
-
0.00049
-
4-[[methyl(1-[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]piperidin-4-yl)amino]methyl]benzoic acid
-
-
5e-06
-
4-[[methyl(3-[methyl[2-([4-[4-(1,3-oxazol-2-yl)phenoxy]phenyl]amino)-2-oxoethyl]amino]propyl)amino]methyl]benzoic acid
-
-
1.6e-05
-
4-[[[3-[(2-[[4-(2-fluorophenoxy)phenyl]amino]-2-oxoethyl)(methyl)amino]propyl](methyl)amino]methyl]benzoic acid
-
-
1.7e-05
-
4-[[[3-[(2-[[4-(4-chlorophenoxy)phenyl]amino]-2-oxoethyl)(methyl)amino]propyl](methyl)amino]methyl]benzoic acid
-
-
6e-06
-
4-[[[3-[(2-[[4-(4-fluorophenoxy)phenyl]amino]-2-oxoethyl)(methyl)amino]propyl](methyl)amino]methyl]benzoic acid
-
-
3e-06
-
4-[[[3-[[2-[(4-benzylphenyl)amino]-2-oxoethyl](methyl)amino]propyl](methyl)amino]methyl]benzoic acid
-
-
0.018
-
5-oxo-5-[[4-(phenylmethoxy)phenyl]amino]pentanoic acid
-
IC50 above 0.018 mM
2.8e-05
-
5-[(methyl[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]amino)methyl]furan-2-carboxylic acid
-
-
5e-05
-
acetic acid (1-[2-[4-(benzothiazol-2-yloxy)phenyl]ethyl]piperidin-4-ylcarbamoyl)methyl ester
-
-
2.1e-05
-
acetic acid [1-[4-(benzothiazol-2-yloxy)benzyl]piperidin-4-ylcarbamoyl]methyl ester
-
-
0.0005
-
bestatin
-
-
0.63
-
Captopril
-
-
3.5e-05
-
N-(1-[2-[4-(benzothiazol-2-yloxy)phenyl]ethyl]piperidin-4-yl)acetamide
-
-
8e-06
-
N-[1-[4-(benzothiazol-2-yloxy)benzyl]piperidin-4-yl]-2-hydroxyacetamide
-
-
1.2e-05
-
N-[1-[4-(benzothiazol-2-yloxy)benzyl]piperidin-4-yl]acetamide
-
-
0.00017
-
N-[3(R)-[(hydroxyamino)carbonyl]-2-benzyl-1-oxopropyl]-L-alanine
-
pH 8.0, temperature not specified in the publication
-
2.2e-05
-
N1-(2-aminoethyl)-N5-(4-phenoxyphenyl)-L-glutamamide hydrochloride
-
-
2.2e-05
-
N1-(2-carboxyethyl)-N5-(4-phenoxyphenyl)-L-glutamamide trifluoroacetate
-
-
2e-05
-
N1-(2-hydroxyethyl)-N5-(4-phenoxyphenyl)-L-glutamamide trifluoroacetate
-
-
1.7e-05
-
N1-(3-carboxypropyl)-N5-(4-phenoxyphenyl)-L-glutamamide trifluoroacetate
-
-
1.9e-05
-
N1-(4-carboxybutyl)-N5-(4-phenoxyphenyl)-L-glutamamide bistrifluoroacetate
-
-
2.5e-05
-
N1-hydroxy-N5-[4-(phenylmethoxy)phenyl]-L-glutamamide trifluoroacetate
-
-
0.0093
-
N1-[4-(phenylmethoxy)phenyl]-D-aspartamine
-
-
0.0072
-
N1-[4-(phenylmethoxy)phenyl]-D-glutamine trifluoroacetate
-
-
0.0054
-
N1-[4-(phenylmethoxy)phenyl]-L-aspartamine trifluoroacetate
-
-
0.002
-
N1-[4-(phenylmethoxy)phenyl]-L-glutamamide hydrochloride
-
IC50 above 0.002 mM
0.00068
-
N1-[4-(phenylmethoxy)phenyl]-L-glutamine trifluoroacetate
-
-
4e-06
-
N2-methyl-N-(4-phenoxyphenyl)-N2-[4-(1H-tetrazol-5-yl)benzyl]glycinamide
-
-
0.00011
-
N2-methyl-N2-[3-[methyl(4-oxobutyl)amino]propyl]-N-(4-phenoxyphenyl)glycinamide
-
-
1.8e-05
-
N2-methyl-N2-[4-[methyl(4-oxobutyl)amino]butyl]-N-(4-phenoxyphenyl)glycinamide
-
-
0.00016
-
N2-[3-(dimethylamino)propyl]-N2-methyl-N-(4-phenoxyphenyl)glycinamide
-
-
9e-05
-
N2-[3-[benzyl(methyl)amino]propyl]-N2-methyl-N-(4-phenoxyphenyl)glycinamide
-
-
3.3e-05
-
N2-[4-[(aminooxy)sulfinyl]benzyl]-N2-methyl-N-(4-phenoxyphenyl)glycinamide
-
-
0.0011
-
N4-[4-(phenylmethoxy)phenyl]-L-aspartamine trifluoroacetate
-
-
1.9e-05
-
N5-(4-phenoxyphenyl)-L-glutamine
-
-
0.018
-
N5-phenyl-L-glutamamide dihydrochloride
-
IC50 above 0.018 mM
0.0026
-
N5-[(4-phenoxy)-3-pyridyl]-L-glutamamide tristrifluoroacetate
-
-
0.00073
-
N5-[3-(phenylmethoxy)phenyl]-L-glutamine methyl ester
-
-
0.0097
-
N5-[4-(1H-pyrrol-1-yl)phenyl]-L-glutamamide hydrochloride
-
-
1.7e-05
-
N5-[4-(2-hydroxy-3-phenylpropoxy)phenyl]-L-glutamine trifluoroacetate
-
-
0.0028
-
N5-[4-(2-methylphenoxy)phenyl]-L-glutamamide hydrochloride
-
-
1.8e-05
-
N5-[4-(2-oxo-3-phenylpropoxy)phenyl]-L-glutamine trifluoroacetate
-
-
4.6e-05
-
N5-[4-(2-phenylethoxy)phenyl]-L-glutamine
-
-
0.00015
-
N5-[4-(3-methylphenoxy)phenyl]-L-glutamamide hydrochloride
-
-
3.1e-05
-
N5-[4-(3-phenylpropoxy)phenyl]-L-glutamine
-
-
2.9e-05
-
N5-[4-(4-(3-furyl)phenoxy)phenyl]-L-glutamamide trifluoroacetate
-
-
1.3e-05
-
N5-[4-(4-methylphenoxy)phenyl]-L-glutamamide hydrochloride
-
-
0.018
-
N5-[4-(cyclohexyloxy)phenyl]-L-glutamamide
-
IC50 above 0.018 mM
0.008
-
N5-[4-(N-methyl-N-phenylamino)phenyl]-L-glutamine methyl ester trifluoroacetate
-
-
0.00021
-
N5-[4-(N-phenylamino)phenyl]-L-glutamine bistrifluoroacetate
-
-
0.0016
-
N5-[4-(phenylmethoxy)phenyl]-D-glutamine hydrochloride
-
-
2.3e-05
-
N5-[4-(phenylmethoxy)phenyl]-L-glutamamide trifluoroacetate
-
-
6e-05
-
N5-[4-(phenylmethoxy)phenyl]-L-glutamine 1,1-dimethylethyl ester
-
-
2e-05
-
N5-[4-(phenylmethoxy)phenyl]-L-glutamine hemitrifluoroacetate
-
-
3.9e-05
-
N5-[4-(phenylmethoxy)phenyl]-L-glutamine methyl ester hydrochloride
-
-
2.1e-05
-
N5-[4-benzylphenyl]-L-glutamamide trifluoroacetate
-
-
0.018
-
N5-[4-methoxyphenyl]-L-glutamine methyl ester trifluoroacetate
-
IC50 above 0.018 mM
2.2e-05
-
N5-[4-[4-(1H-pyrrol-1-yl)phenoxy]phenyl]-L-glutamine hemitrifluoroacetate
-
-
6e-06
-
N6-[4-(4-methylphenoxy)phenyl]-L-homoglutamine trifluoroacetate
-
-
7.9e-05
-
S-(4-cyclohexylbenzyl)-N-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-cysteine
-
-
2.4e-05
-
S-(4-tert-butylbenzyl)-N-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-cysteine
-
-
0.00021
-
S-[(4-cyclohexylphenyl)(phenyl)methyl]-N-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-cysteine
-
-
5.5e-05
-
S-[1-(4-cyclohexylphenyl)-1-methylethyl]-N-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-cysteine
-
-
7.9e-05
-
S-[1-methyl-1-[4-(1-methylethyl)phenyl]ethyl]-N-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-cysteine
-
-
0.00018
-
S-[1-[4-(1-methylethyl)phenyl]butyl]-N-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-cysteine
-
-
5.5e-05
-
S-[1-[4-(1-methylethyl)phenyl]ethyl]-N-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-cysteine
-
-
0.00051
-
S-[1-[4-(1-methylethyl)phenyl]pentyl]-N-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-cysteine
-
-
6.7e-05
-
S-[1-[4-(1-methylethyl)phenyl]propyl]-N-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-cysteine
-
-
0.00052
-
S-[2-methyl-1-[4-(1-methylethyl)phenyl]propyl]-N-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-cysteine
-
-
0.0009
-
S-[4-(diethylamino)benzyl]-N-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-cysteine
-
-
9.1e-05
-
S-[[4-(1-methylethyl)phenyl](phenyl)methyl]-N-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-cysteine
-
-
0.00088
-
[(2R)-2-[[4-(4-chlorophenoxy)phenoxy]methyl]piperidin-1-yl]acetic acid
-
-
-
SPECIFIC ACTIVITY [µmol/min/mg]
SPECIFIC ACTIVITY MAXIMUM
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
0.185
-
-
-
0.22
-
-
-
0.31
-
-
mutant E296N
0.49
-
-
mutant E296D
0.53
-
-
-
0.692
-
-
in comparison with mutant enzymes
additional information
-
-
-
additional information
-
-
-
additional information
-
-
-
additional information
-
-
-
pH OPTIMUM
pH MAXIMUM
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
7.5
8.5
-
-
7.5
-
-
-
7.6
8.9
-
-
8
-
-
assay at
pH RANGE
pH RANGE MAXIMUM
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
6.5
8.5
-
about 25% of activity maximum at pH 6.5 and 8.5
TEMPERATURE OPTIMUM
TEMPERATURE OPTIMUM MAXIMUM
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
20
-
-
assay at
20
-
-
activity assay
37
-
-
assay at
37
-
-
-
37
-
-
assay at
TEMPERATURE RANGE
TEMPERATURE MAXIMUM
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
22
-
-
22C: 53% of activity maximum, 50C: 33% of activity maximum
pI VALUE
pI VALUE MAXIMUM
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
5.1
-
-
chromatofocusing
5.1
-
-
isoform 1
5.1
-
-
chromatofocusing
5.24
-
-
short-form enzyme
5.3
-
-
isoform 2
5.4
-
-
chromatofocusing, isoelectric focusing, in absence of SH reducing reagents
5.5
-
-
chromatofocusing
5.7
-
-
chromatofocusing, isoelectric focusing, in presence of SH reducing reagents
5.76
-
-
long-form enzyme
6.1
-
-
isoelectric focusing and chromatofocusing
6.2
-
-
chromatofocusing
SOURCE TISSUE
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
SOURCE
-
carotid atherosclerotic lesion
Manually annotated by BRENDA team
-
primary effusion lymphoma
Manually annotated by BRENDA team
-
intraluminal thrombus
Manually annotated by BRENDA team
-
spiral ganglion cell in the cochlea
Manually annotated by BRENDA team
-
used as control for the expression of 5-LO pathway enzymes
Manually annotated by BRENDA team
-
esophageal and duodenal
Manually annotated by BRENDA team
P30349
esophageal and duodenal
Manually annotated by BRENDA team
-
inactive form of enzyme
Manually annotated by BRENDA team
-
of the nasal airway
Manually annotated by BRENDA team
-
basal cells
Manually annotated by BRENDA team
P30349
basal cells
Manually annotated by BRENDA team
-
neurons in the ganglion cell layer
Manually annotated by BRENDA team
-
high expression level
Manually annotated by BRENDA team
-
used as control for the expression of 5-LO pathway enzymes
Manually annotated by BRENDA team
-
used as control for the expression of 5-LO pathway enzymes
Manually annotated by BRENDA team
-
classical Hodgkins disease
Manually annotated by BRENDA team
-
used as control for the expression of 5-LO pathway enzymes
Manually annotated by BRENDA team
Mus musculus BALB/c
-
-
-
Manually annotated by BRENDA team
-
alveolar macrophage
Manually annotated by BRENDA team
-
bone marrow-derived
Manually annotated by BRENDA team
Mus musculus BALB/c
-
bone marrow-derived
-
Manually annotated by BRENDA team
-
enzyme expression analysis, overview
Manually annotated by BRENDA team
P30349
peripheral
Manually annotated by BRENDA team
-
axon in the optic nerve
Manually annotated by BRENDA team
-
inner plexiform layer of the retina
Manually annotated by BRENDA team
-
enzyme expression analysis in healthy and atopic dogs, overview
Manually annotated by BRENDA team
-
lamina II of the spinal cord
Manually annotated by BRENDA team
P30349
enzyme expression analysis, LTA4h mRNA is expressed in both spinal neurons and microglia, overview
Manually annotated by BRENDA team
-
squamous epithelium of hamster oral mucosa
Manually annotated by BRENDA team
additional information
-
enzyme is higher in columnar-lined esophagus, dysplastic, and total esophageal adenocarcinoma tissues than in basal cells of esophageal epithelium, however enzyme is expressed in the parabasal cells of esophageal squamous epithelium, enzyme is also overexpressed in other cancers, including colon and lung cancers; esophageal adenocarcinoma tumor
Manually annotated by BRENDA team
additional information
P30349
esophageal adenocarcinoma tumor; esophageal aquamous epithelial cells do not express enzyme, even in the presence of reflux esophagitis
Manually annotated by BRENDA team
additional information
P19602
mRNA is distributed in liver, brain, lung, heart, kidney, and highly expressed in the intestine and spleen
Manually annotated by BRENDA team
additional information
-
immunohistochemical analysis, overview
Manually annotated by BRENDA team
LOCALIZATION
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
GeneOntology No.
LITERATURE
SOURCE
additional information
-
-
-
Manually annotated by BRENDA team
additional information
-
the short- and long-form mRNA expression levels of selected number of cell types is analysed by quantitative RT-PCR
-
Manually annotated by BRENDA team
additional information
-
the subcellular distribution is cellspecific
-
Manually annotated by BRENDA team
additional information
-
association with the plasma membrane during restricted infection with HIV-1
-
Manually annotated by BRENDA team
PDB
SCOP
CATH
ORGANISM
Saccharomyces cerevisiae (strain ATCC 204508 / S288c)
Saccharomyces cerevisiae (strain ATCC 204508 / S288c)
Saccharomyces cerevisiae (strain ATCC 204508 / S288c)
MOLECULAR WEIGHT
MOLECULAR WEIGHT MAXIMUM
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
42000
46000
-
gel filtration
45000
-
-
gel filtration
48000
49000
-
gel filtration
49000
50000
-
gel filtration
50000
-
-
gel filtration
59000
-
-
novel short-form mRNA
68000
-
-
determinend by SDS-PAGE and Western Blot analysis
69000
-
-
gel filtration
69000
-
-
calculated from DNA sequence
69000
-
-
-
SUBUNITS
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
?
-
x * 70000, SDS-PAGE
?
-
x * 67000-71000, SDS-PAGE
?
-
x * 69000, SDS-PAGE
?
-
x * 70000, SDS-PAGE
?
-
x * 72000, SDS-PAGE
?
-
x * 69000, SDS-PAGE
?
-
x * 70000, SDS-PAGE
?
-
x * 69000, SDS-PAGE, mutant enzymes
?
P19602
x * 68758, calculated from amino acid sequence
monomer
-
1 * 68000, SDS-PAGE
monomer
-
1 * 68000-70000, SDS-PAGE
monomer
-
1 * 69000
POSTTRANSLATIONAL MODIFICATION
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
additional information
-
enzyme is susceptible to proteolytic digestion
Crystallization/COMMENTARY
ORGANISM
UNIPROT ACCESSION NO.
LITERATURE
crystal structure of enzyme complexed with bestatin
-
crystal structure of enzyme in complex with captopril, thioamine or hydroxamic acid
-
in complex with inhibitor N-[3(R)-[(hydroxyamino)carbonyl]-2-benzyl-1-oxopropyl]-L-alanine, to 1.9 A resolution, space group P212121. The inhibitor binds along the sequence signature for M1 aminopeptidases, GXMEN. It exhibits bidentate chelation of the catalytic zinc and binds to LTA4H's enzymatically essential carboxylate recognition site. The inhibitor binds in an extended beta-sheet conformation between the zinc ion and Arg563. The carboxyl moiety forms two hydrogen bonds with Arg563, and the hydroxamate moiety chelates the zinc ion in a bidentate fashion
-
liquid-liquid diffusion method, with 28% (w/v) polyethylene glycol, 100 mM imidazole pH 7.2, and 5 mM YbCl3
-
molecular docking studies with inhibitors. Position and size of substituted groups plays a key role in the binding conformation of the compounds. Compounds without branches, and p-substituted compounds tend to bind LTA4H in the channel, forming a hydrogen bond between the pyrrolidine nitrogen atom and Gly269 main-chain oxygen atom. o- or m-Substituted compounds can stay at the entrance part of the pocket in a reversed orientation with three hydrogen bonds, the nitrogen atom to Gln136, the oxygen atom connected to alkyl group to His295, and the oxygen atom connected to bibenzyl to Gly268 main-chain nitrogen atom
-
mutant enzyme E296Q in complex with inhibitors RB3040 and RB3041, and substrate, liquid-liquid diffusion method, using 28% (w/v) polyethylene glycol, 50 mM Na acetate, 100 mM imidazole (pH 6.8), and 5 mM YbCl3
-
the structure of LTA4H in complex with the competitive inhibitor is determined
-
wild-type enzyme and mutant D375N
-
wild-type enzyme and mutant E271Q
-
pH STABILITY
pH STABILITY MAXIMUM
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
7.8
-
-
unstable in aqueous buffer solutions at 25C, half-life less than 10 s
7.8
-
-
without any organic solvent at 25C the half-life is less than 10 s, stability increases at higher pH
TEMPERATURE STABILITY
TEMPERATURE STABILITY MAXIMUM
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
25
-
-
unstable in aqueous buffer solutions at pH 7.8, half-life less than 10 s
25
-
-
without any organic solvent at pH 7.4 the half-life is less than 10 s, stability increases at lower temperature
56
-
-
1 h, complete loss of activity
70
-
-
5 min, complete loss of activity
ORGANIC SOLVENT
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
additional information
-
enzyme is unstable in aqueous buffer solutions at pH 7.8 and 25C and nonenzymatically hydrolysed, half-life less than 10 s
additional information
-
without any organic solvent at pH 7.4 and 25C the half-life is less than 10 s
STORAGE STABILITY
ORGANISM
UNIPROT ACCESSION NO.
LITERATURE
-20C, 95% of activity after 12 days
-
4C, 50% loss of activity after 12 days
-
4C, 25 mM HEPES, pH 8.0 the apoenzyme is stable for more than 5 weeks
-
4C, stable for 1 week
-
4C, stable for at least 1 month
-
-20C, 30% glycerol, stable for at least 2 months
-
Purification/COMMENTARY
ORGANISM
UNIPROT ACCESSION NO.
LITERATURE
recombinant enzyme
-
wild-type and mutant enzymes
-
recombinant enzyme, expression in Escherichia coli as a fusion protein with ten additional amino acids at the amino terminus
-
recombinant enzyme
-
using metal affinity chromatography, the His tag is removed by digestion with His6-TEV protease
-
Cloned/COMMENTARY
ORGANISM
UNIPROT ACCESSION NO.
LITERATURE
mRNA is distributed in liver, brain, lung, heart, kidney, and highly expressed in the intestine and spleen
P19602
the enzyme is encoded in the lta4h locus, lta4h interacts with the TNF signaling pathway
-
expressed in Escherichia coli JM101 cells
-
expressed in Sf-9 cells
-
expression in Escherichia coli
-
high-level expression enzyme in Spodoptera frugiperda cells infected with baculovirus vector
-
identification of two isoforms of the mRNA, short and long, by using a sequential reverse transcriptase (RT)-PCR mapping approach, both enzyme mRNAs are expressed in blood cells, endothelial cells, smooth muscle cells, fibroblasts and tumor cells
-
LTA4H gene, genotyping
-
overexpressed in Escherichia coli YA21 using pEX85 vector
-
the enzyme is encoded in the lta4h locus, lta4h interacts with the TNF signaling pathway. LthA4 genotyping in leprosy patients from Vietnam and Nepal, overview
-
wild-type and mutant enzymes expressed in Escherichia coli
-
expression in Escherichia coli as a fusion protein with ten additional amino acids at the amino terminus
-
semiquantitative LTA4H expression analysis in peripheral nerves and spinal cord, overview
P30349
expression in Escherichia coli and in Sf9 cells, using the baculovirus system
-
into the pYES2.1-Topo vector for expression of the recombinant proteins in Saccharomyces cerevisiae 1971
-
EXPRESSION
ORGANISM
UNIPROT ACCESSION NO.
LITERATURE
significantly higher mRNA expression of the key enzymes 5-lipoxygenase, 5-LO activating protein, leukotriene A4 hydrolase, and prostaglandin E synthase 1 and their PGE receptors 2 and 3, occur in canine atopic dermatitis, a chronic inflammatory skin disease, overview
-
knockdown of LTA4H inhibits anchorage-independent growth of HCT116 colon cancer cells
-
the enzyme is induced by HIV-1 infection, facilitating the protein transformation from the cytosol to the plasma membrane, which is linked to cathepsin B- and caspase 9, 3-dependent apoptosis, overview
-
the enzyme expression is upregulated in keratinocytes by 2-chloroethyl ethyl sulfide via p38MAP kinase signaling pathway, inhibition of p38 MAP kinase suppresses CEES-induced expression of LTA4 hydrolase, overview
-
ENGINEERING
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
D368N
-
epoxide hydrolase activity: 72% of Km of wild type enzyme, aminopeptidase activity: 107% of Km of wild type enzyme
D371N
-
epoxide hydrolase activity: 51% of Km of wild type enzyme, aminopeptidase activity: 77% of Km of wild type enzyme
D373N
-
epoxide hydrolase activity: 43% of Km of wild type enzyme, aminopeptidase activity: 101% of Km of wild type enzyme
D375A
-
near-complete loss of the epoxide hydrolase activity, aminopeptidase activity exhibits unsaturable enzyme kinetic
D375A
-
mutant with reduced activity
D375E
-
complete loss of the epoxide hydrolase activity, aminopeptidase activity: 152% of Km of wild type enzyme
D375N
-
complete loss of the epoxide hydrolase activity, aminopeptidase activity exhibits unsaturable enzyme kinetic
E271A
-
complete loss of the epoxide hydrolase and aminopeptidase activities
E271D
-
complete loss of the epoxide hydrolase and aminopeptidase activities
E271Q
-
complete loss of the epoxide hydrolase and aminopeptidase activities
E296Q
-
mutant with severely reduced activity
E297A
-
30% hydrolase activity, 25% peptidase activity, in comparison to 100% hydrolase- and peptidase activity of wild-type enzyme
E297D
-
17% hydrolase activity, 38% peptidase activity, in comparison to 100% hydrolase- and peptidase activity of wild-type enzyme
E297K
-
13% hydrolase activity, 16% peptidase activity, in comparison to 100% hydrolase- and peptidase activity of wild-type enzyme
E297Q
-
104% hydrolase activity, 14% peptidase activity, in comparison to 100% hydrolase- and peptidase activity of wild-type enzyme
E318A
-
the exposure of mutant enzyme to leukotriene A4, leukotriene methyl ester or leukotriene ethyl ester results in covalent modification of peptide K21 to the same extent as for wild-type enzyme
E319K
-
0% hydrolase activity, 12% peptidase activity, in comparison to 100% hydrolase- and peptidase activity of wild-type enzyme
G268A
-
epoxide hydrolase activity: 97% of Km of wild type enzyme, aminopeptidase activity: 73% of Km of wild type enzyme
G269A
-
epoxide hydrolase activity: 202% of Km of wild type enzyme, aminopeptidase activity: 66% of Km of wild type enzyme
H139Q
-
epoxide hydrolase activity: 167% of Km of wild type enzyme, aminopeptidase activity: 359% of Km of wild type enzyme
N272A
-
epoxide hydrolase activity: 30% of Km of wild type enzyme, aminopeptidase activity: 221% of Km of wild type enzyme
Q134A
-
epoxide hydrolase activity exhibits unsaturable enzyme kinetics within the range observed, aminopeptidase activity: 157% of Km of wild type enzyme
Q134L
-
significantly increased epoxide hydrolase activity, aminopeptidase activity: 87% of Km of wild type enzyme
Q134N
-
epoxide hydrolase activity: 148% of Km of wild type enzyme, aminopeptidase activity: 108% of Km of wild type enzyme
Q136A
-
epoxide hydrolase activity: 67% of Km of wild type enzyme, aminopeptidase activity: 108% of Km of wild type enzyme
Q136L
-
epoxide hydrolase activity: 179% of Km of wild type enzyme
Q136N
-
epoxide hydrolase activity: 18% of Km of wild type enzyme, aminopeptidase activity: 24% of Km of wild type enzyme
S379A
-
26% hydrolase activity, 4% peptidase activity, in comparison to 100% hydrolase- and peptidase activity of wild-type enzyme
S380A
-
54% hydrolase activity, 68% peptidase activity, in comparison to 100% hydrolase- and peptidase activity of wild-type enzyme
S415D
-
significantly reduced epoxide hydrolase activity, little effect on aminopeptidase activity
S415E
-
significantly reduced epoxide hydrolase activity, little effect on aminopeptidase activity
S415Q
-
no effect on enzyme activity
S415T
-
little effect on enzyme activity
Y267F
-
epoxide hydrolase activity: 58% of Km of wild type enzyme, aminopeptidase activity: 64% of Km of wild type enzyme
Y378F
-
173% hydrolase activity, 43% peptidase activity, in comparison to 100% hydrolase- and peptidase activity of wild-type enzyme, mutant enzyme is resistant to suicide inactivation
Y378F
-
products are leukotriene B4 and 5S,12R-dihydroxy-6,10-trans-8,14-cis-eicosatetraenic acid, 203% hydrolase activity, 81% peptidase activity, in comparison to 100% hydrolase- and peptidase activity of wild-type enzyme
Y378F
-
mutant is only partially protected against inactivation by leukotriene methyl ester and leukotriene ethyl ester
Y378Q
-
34% hydrolase activity, 1.6% peptidase activity, in comparison to 100% hydrolase- and peptidase activity of wild-type enzyme, mutant enzyme is resistant to suicide inactivation
Y378Q
-
products are leukotriene B4 and 5S,12R-dihydroxy-6,10-trans-8,14-cis-eicosatetraenic acid, 45% hydrolase activity, 3% peptidase activity, in comparison to 100% hydrolase- and peptidase activity of wild-type enzyme
Y378Q
-
mutant is only partially protected against inactivation by leukotriene methyl ester and leukotriene ethyl ester
Y384F
-
0% hydrolase activity, 13% peptidase activity, in comparison to 100% hydrolase- and peptidase activity of wild-type enzyme
E296D
-
decrease of inhibitor potency of bestatin in comparison to wild-type enzyme, but the inhibitor potencies of alpha-oxo-beta-amino carboxylic ester, a thioamine and amino hydroxamic acid is identical for mutant and wild-type enzyme
E296N
-
decrease of inhibitor potency of bestatin in comparison to wild-type enzyme, but the inhibitor potencies of alpha-oxo-beta-amino carboxylic ester, a thioamine and amino hydroxamic acid is identical for mutant and wild-type enzyme
D399A
-
little effect on catalysis
E341Q
-
101% hydrolase activity, 0.07% peptidase activity, in comparison to 100% hydrolase- and peptidase activity of wild-type enzyme
E363Q
-
2.1% hydrolase activity, 0.05% peptidase activity, in comparison to 100% hydrolase- and peptidase activity of wild-type enzyme
F424Y
-
39.5% hydrolase activity, 147% peptidase activity, in comparison to 100% hydrolase- and peptidase activity of wild-type enzyme
H340Q
-
1.5% hydrolase activity, 0.7% peptidase activity, in comparison to 100% hydrolase- and peptidase activity of wild-type enzyme
H344Q
-
1% hydrolase activity, 0.2% peptidase activity, in comparison to 100% hydrolase- and peptidase activity of wild-type enzyme
N362E
-
large reduction in activity, mutant exhibits an altered pH dependence of catalysis, reduced chloride activation, and reduced zinc affinity and content
N362L
-
large reduction in activity, mutant exhibits an altered pH dependence of catalysis, reduced chloride activation, and reduced zinc affinity and content
N362Q
-
mutation causes minor catalytic defects
W365L
-
little effect on catalysis
Y244F
-
leukotriene A4 hydrolase mutant
Y256F
-
leukotriene A4 hydrolase mutant
Y429F
-
16.4% hydrolase activity, 0.6% peptidase activity, in comparison to 100% hydrolase- and peptidase activity of wild-type enzyme
additional information
-
screening for mutagenized zebrafish larvae phenotypes that differ in their ability to control the replication of Mycobacterium marinum, overview. Three classes of mutants that are hypersusceptible to Mycobacterium marinum infection, one of which mapps to the lta4h locus. The phenotype is not reversible by addition of exogenous LTB4. Induced lta4h deficiency in either wild-type or mutant larvae compromises neither mycobacterially-induced recruitment to the hindbrain ventricle nor bacterial phagocytosis. Lta4h deficiency compromises TNF induction and phenotypically resembles TNF signaling deficiency
M270L
-
epoxide hydrolase activity: 21% of Km of wild type enzyme, aminopeptidase activity: 189% of Km of wild type enzyme
additional information
-
positive correlation between LTA4H polymorphism and the amount of LTB4 produced in vitro by granulocytes from the affected individuals. Heterozygosity at LTA4H is also associated with increased LTB4 production in vivo resulting in enhanced protection from TB or leprosy
additional information
-
mutations in the leukotriene A4 hydrolase gene result in decreased lta4h mRNA expression and increased susceptibility to Mycobacterial infection. lta4h mutations confer hypersusceptibility independent of LTB4 reduction, by redirecting eicosanoid substrates to anti-inflammatory lipoxins. The resultant anti-inflammatory state permits increased mycobacterial proliferation by limiting production of tumor necrosis factor. Lta4h deficiencies result in an immunoregulatory phenotype, overview. Two single-nucleotide polymorphisms are rs1978331 and rs2660898, overview
additional information
-
two single-nucleotide polymorphisms within the LTA4H gene, rs17525488 and rs2540493, are protective against asthma in individuals from Mexico and Puerto Rico. Among the Mexican patients, LTA4H polymorphisms are associated with baseline lung function and IgE levels. Identification of a gene-gene interaction between LTA4H, rs17525488, and arachidonate 5-lipoxygenase-activating protein gene ALOX5AP, rs1050739
additional information
-
a single-nucleotide polymorphism and a particular haplotype for the LTA4H gene are linked to an increased risk for the development of asthma, overview
E296Q
-
decrease of inhibitor potency of bestatin in comparison to wild-type enzyme, but the inhibitor potencies of alpha-oxo-beta-amino carboxylic ester, a thioamine and amino hydroxamic acid is identical for mutant and wild-type enzyme
additional information
-
bone marrow cells from LTA4H-/- mice injected into 5LO-/- mice, defective for 5-lipoxygenase, restores the ability to synthesize LTB4, overview
APPLICATION
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
medicine
-
the enzyme catalyses the hydrolysis of leukotriene A4 into the proinflammatory substance leukotriene B4; the product is a classical chemoattractant, triggers adherence and aggregation of leukocytes to the endothelium, modulates immune responses, participates in the host-defence against infections and is a mediator of PAF-induced lethal shock
medicine
-
the enzyme catalyses the hydrolysis of leukotriene A4 into the proinflammatory substance leukotriene B4
medicine
-
the 5-Lox/LTA4H pathway is involved in 7,12-dimethylbenz[alpha]anthracene induced oral carcinogenesis and may be targeted for chemoprevention of oral cancer
diagnostics
-
LTA4H genes are risk factors for asthma in two different ethnic groups, individuals from Mexico and Puerto Rico
medicine
-
the enzyme catalyses the hydrolysis of leukotriene A4 into the proinflammatory substance leukotriene B4; the product is a classical chemoattractant, triggers adherence and aggregation of leukocytes to the endothelium, modulates immune responses, participates in the host-defence against infections and is a mediator of PAF-induced lethal shock
medicine
-
the enzyme catalyses the hydrolysis of leukotriene A4 into the proinflammatory substance leukotriene B4
medicine
-
enzyme overexpression appears to be an early event in esophageal adenocarcinogenesis and is a potential target for the chemoprevention of esophageal adenocarcinogenesis; the enzyme catalyses the hydrolysis of leukotriene A4 into the proinflammatory substance leukotriene B4
medicine
-
the enzyme catalyses the hydrolysis of leukotriene A4 into the proinflammatory substance leukotriene B4; the lipid metabolic activity of enzyme plays a central role in the control of polymorphonuclear leukocyte function and in the development of inflammation, the regulation of enzyme presents a novel potential target for anti-inflammatory therapy
medicine
-
understanding the molecular alterations that influence primary effusion lymphoma development will aid in the identification of novel therapeutic targets, as well as potential risk factors for this desease
medicine
-
findings suggest that agents affecting LTB4 biosynthetic pathway may prove useful for primary or secondary prevention of heart attacks
medicine
-
LTA4H appears to be a promising target for development of drugs for prevention and treatment of atherosclerosis and its associated thrombotic complications
medicine
-
LTA4H is significantly associated with coronary artery disease
medicine
-
inhibition of LTB4 synthesis may be beneficial in the treatment of severe asthma and viral exacerbations of asthma, in which neutrophilic inflammation is more prominent
pharmacology
-
leukotriene 4 hydrolase is a key target for the treatment of cardiovascular disease
medicine
-
the enzyme catalyses the hydrolysis of leukotriene A4 into the proinflammatory substance leukotriene B4
medicine
-
the enzyme catalyses the hydrolysis of leukotriene A4 into the proinflammatory substance leukotriene B4; the product is a classical chemoattractant, triggers adherence and aggregation of leukocytes to the endothelium, modulates immune responses, participates in the host-defence against infections and is a mediator of PAF-induced lethal shock
medicine
-
LTA4H appears to be a promising target for development of drugs for prevention and treatment of atherosclerosis and its associated thrombotic complications
pharmacology
-
inhibition of LTA4H is a potential therapeutic strategy that can modulate key aspects of asthma
pharmacology
Mus musculus BALB/c
-
inhibition of LTA4H is a potential therapeutic strategy that can modulate key aspects of asthma
-
medicine
-
the enzyme catalyses the hydrolysis of leukotriene A4 into the proinflammatory substance leukotriene B4; the product is a classical chemoattractant, triggers adherence and aggregation of leukocytes to the endothelium, modulates immune responses, participates in the host-defence against infections and is a mediator of PAF-induced lethal shock
medicine
P30349
enzyme overexpression appears to be an early event in esophageal adenocarcinogenesis and is a potential target for the chemoprevention of esophageal adenocarcinogenesis; the enzyme catalyses the hydrolysis of leukotriene A4 into the proinflammatory substance leukotriene B4
medicine
-
the enzyme catalyses the hydrolysis of leukotriene A4 into the proinflammatory substance leukotriene B4